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This thesis is dedicated to all those who try and fail…then get up and try again.   
 
This is also dedicated to all those who struggle with addiction.  Though there is 
no substitute for focus and discipline, everybody needs a helping hand once in a 
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Cocaine’s impact on society spans several thousand years, yet its adverse 
effects due to the toll of addiction have only imposed a global problem during the 
last hundred years.  After cocaine was isolated from its natural source, leaves of 
a coca plant, it proved to be a “miracle drug” with numerous pharmacological 
effects.   Its potential for abuse quickly became so prevalent that it became one 
of several drugs targeted by the war on drugs.  A standard treatment for cocaine 
addiction remains elusive though multiple research efforts are currently 
developing a number of candidates.  The majority of pharmacological 
approaches to treating cocaine addiction offer limited benefits that treat 
symptoms of addiction and do not curb long term drug seeking behavior once the 
treatment is over.  A number of protein-based therapeutics have shown promise 
in their ability to hydrolyze cocaine and provide a more pharmacokinetic 
approach to cocaine addiction. In this thesis, the continued development of a 
bacterial enzyme - cocaine esterase – will be explored.  More specifically, 
through PEGylation of CocE, the in vivo activity of the drug has been extended to 
over three days of complete protection against a lethal dose of cocaine in mice, 
providing the best protection to date.  Also, through crystallographic studies and 
mutation of CocE’s primary structure, a mutant with the highest velocity of 
cocaine hydrolysis has been engineered.  The results of these studies 
xiv	  
demonstrate how CocE continues to prove worthy for the application of cocaine 








Cocaine addiction began in this country soon after it was made available 
to the public around the end of the 1800s.  Since this time, the prevalence of 
cocaine addiction in society has fluctuated based on the current tastes of drug 
seekers, but its grip on society has remained entrenched in the population.  The 
ramifications of addiction cover loss of productivity at work and school as well as 
money spent on treatment and rehabilitation.  Unfortunately, no single successful 
treatment currently exists that can curb cocaine craving in addicts.  Providing a 
readily available and universally accepted treatment would reduce the overall 
cost of addiction and provide the addicts with a tool to help them return to the 
state of their lives prior to cocaine craving taking over.   
 In order to provide a treatment for cocaine addiction, researchers have 
pursued several different approaches to this problem.  Behavioral reconditioning 
can be effective if addicts adhere to their chosen mode of distraction from drug 
seeking patterns.  Relapse rates remain too high to allow this approach to stand-
alone.  Advancements in addiction science and pharmaceutical development 
expand the potential field of treatments from small molecules to protein-based 
therapeutics.  Ingesting higher amounts of cocaine and relying on adherence to 
treatment regimens now constitute an Achilles heel in both of these approaches 
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to treatment.  For over 10 years we have been developing an enzyme that can 
address both cocaine toxicity and addiction.  This enzyme not only provides 
immediate reduction of cocaine levels in circulation, but its ability to hydrolyze 
cocaine rapidly enough will prevent animals conditioned to seek out cocaine 
stimulation from continuing to pursue this drug.  Though this enzyme has passed 
phase two clinical trials as a treatment for cocaine toxicity, its application as an 
addiction treatment means that a couple of aspects need addressing.  In order to 
address these deficiencies, a more thorough evaluation of cocaine, its 
pharmacology, and current modes of treatment should first be evaluated.   
 
Coca plant – discovery and use 
Indigenous people from the northwest region of South America found that 
chewing coca leaves energized their mind and body.  The leaves of the 
Erythrozyla genus plants synthesize an alkaloid stimulant, today known as 
cocaine, and humans began to utilize the leaves several thousand years ago.  
The Erythrozylon coca plant, in particular, produces the most cocaine, but only 
grows in a specific climate like that found in the northwest region of South 
America.  The financial and cultural importance of these coca leaves caused 
them to be distributed well outside of this region. [2] 
The coca plant’s initial importance to human civilization revolved around 
religion, sex, and war [3-5].  Early Inca mythology surrounding the origins of the 
coca plant claimed that the first coca plant grew from the remains of a woman 
that lived a promiscuous life [3].  Her conspicuous actions and lifestyle clashed 
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with that of her community, ultimately ending in her murder and dismemberment 
prior to burial.  Both the woman and the plant were referred to as “Mama Coca”.  
A legend inspired by this event alleges that the men of the community would 
carry bags of coca leaves with them but could partake in the leaves only after 
engaging in sexual congress with a woman.  Another religious account from the 
area of modern day Columbia, states that early humans sprang forth from the 
Milky Way the story claims that the first two humans came to earth in a canoe 
containing three plants - cassava, caapi, and coca. [2, 6] 
Coca leaves have been found in the graves of many nobles, warriors, and 
priests who were interred around the northwestern area of South America.  
Accounts from the Incan expansion throughout this region tell tales of warriors 
chewing the coca leaves prior to and during battle.  Ancient carvings of the 
warriors and gods contained swollen cheeks depicting the ritual of coca leaf 
consumption. [2]  Archeological excavations uncovered containers with coca leaf 
remnants and vessels containing lime (calcium carbonate from roasting shells of 
shellfish) indicating that ancient Moche and Quimbaya tribes consumed the 
leaves as early as 4000 years ago.  [2]   
Amerigo Vespucci, the famous Italian cartographer, noted the swollen 
cheeks of the first indigenous people he had sighted in the New World.  Coca 
cultivation and usage were initially recorded and published in Europe by 
Vespucci when he detailed his initial travels to the New World in 1505.  [5] 
Outside of the religious, battlefield, and bedroom customs, coca leaves 
were consumed as part of the daily life of the indigenous peoples, either as a tea 
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or by chewing them throughout the day.  Both of these methods of consumption 
alleviate hunger and provide an energy boost to farmers and laborers.  
Throughout the Spanish colonization of South America, slaves and indentured 
servants were given daily allowances of coca leaves to help them work in the 
gold and silver mines, as well as, on the coca plantations themselves.  Taxes 
collected by the European governors in these areas were often paid in the form 
of coca leaves, which the self-appointed government officials would then in turn 
dispense to the locals as payment for services rendered [2].  
Though the ritual of chewing coca leaves continues to the present day, the 
alkaloid compound responsible for all physiological and psychological effects was 
sought out by a new generation of consumers in Europe shortly after its 
introduction to the area.  Cocaine, [methyl (1R,2R,3S,5S)-3- (benzoyloxy)-8-
methyl-8-azabicyclo[3.2.1] octane-2-carboxylate], was isolated in the mid-19th 
century, and soon after, was being synthesized by laboratories and companies 
looking to profit from cocaine’s various effects on the body and mind.   
 
Isolating cocaine 
Soon after Europeans gained an appreciation for coca leaves, research 
efforts began to understand the molecular basis of coca leaves’ physiological 
effects.  The cocaine molecule was isolated in 1859 by the German chemist 
Albert Niemann during his doctoral thesis work.  He wrote of the alkaloid's 
"colourless transparent prisms" and said that, "Its solutions have an alkaline 
reaction, a bitter taste, promote the flow of saliva and leave a peculiar numbness, 
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followed by a sense of cold when applied to the tongue." Because of the alkaloid 
classification of the compound, Niemann named the molecule "cocaine" [7].  
Tragically, only one year after his isolation of cocaine, Niemann died due to a 
lung condition possibly from inhaling the sulfur mustards used during this 
dissertation research.  After Niemann’s death in 1861, his colleague, Wilhelm 
Lossen, continued the research on cocaine and was able to identify the chemical 
formula of cocaine [4]. 
 
 
Cocaine, (2-β-carbomethoxy-3-β-benzoxytropane), contains one internal 
ester bond shown to be a site of hydrolysis during bodily processing of the drug.  
The synthesis of cocaine can be achieved through reacting starting materials 
ecgonine and benzoyl chloride, a process discovered by Richard Willstätter in 
1901, with an additional step to add the methyl ester on the tropane ring.  Sir 
Robert Robinson perfected a more efficient method with higher yield in 1917 [3, 
8]. 
	  






Cocaine’s use in Europe and in the United States exploded after Dr. Karl 
Köller demonstrated the use of cocaine as a topical local anesthetic agent for eye 
surgery in 1884.  Due to the success of the surgery, cocaine became available 
almost overnight throughout the western world and was produced by many 
pharmaceutical companies.  Prior to Dr. Köller’s experiment, cocaine was rarely 
available in the US and was sold, where it could be found, for around one dollar 
per grain (~65 milligrams).  By 1887, the drug was readily available in most drug 
stores and could be purchased for two cents per grain [4].  Cocaine was added to 
wines and elixirs designed to promote, enliven, and ‘tonify’ the mind of 
consumers.  It was even an ingredient in the early forms of the popular beverage 
CocaCola™. 
The two branches of pharmaceutical companies at that time, ethical and 
patent medicine, produced cocaine both in its powder form and also as a key 
ingredient to many medical remedies.  Most of these remedies came in the form 
of a liquid tonic that claimed to cure a wide range of disorders from all sorts of 
physical, mental and emotional natures.  Ironically, one of the first uses of 
cocaine was as a curative treatment for opiate addiction [4]. 
As the availability and acceptance of cocaine grew, so did its potential for 
abuse.  Doctors found other uses for the drug through its anesthetizing abilities, 
but they too began to abuse the drug.  While some physicians treated ether, 
alcohol, and opiate addictions with cocaine, more problems arose due to cocaine 
addiction as a result of these treatments.  The transition of cocaine from “miracle 
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drug” to evil destroyer of society was evident when the drug was included in the 
Harrison Narcotic Act of 1914 [3, 4]. 
 
Though cocaine has never been decriminalized since that time, its use in 
the United States has never disappeared entirely, and its resurgence in 
popularity has helped shape popular culture.  During the 1950s and 60s, cocaine 
use increased with the beat and hippie generations iconoclastic approach to 
“square” living.  Drug use had been demonized by society and as these 
generations began questioning society’s view of right and wrong, their 
exploration of new perspectives included experimenting with mind-altering 
substances [3]. 
By the end of the 60’ s and through the 70s, cocaine use slackened, 
around the time that US President Richard Nixon enacted the new federal policy 
of the “War on Drugs”.  Cocaine once again became popular in the 1980’s club 
culture.  Its widespread use surpassed that of the previous generation, primarily 
due to the establishment and maturity of South American drug cartels and 
expanding the production and availability of cocaine.  During this time, production 
in Columbia grew to all-time highs and the illegal supply in this country grew 
larger than it had ever been [9]. 
The 1980s also saw the next generation of cocaine evolve as cocaine was 
formulated into crack cocaine, and the drug took on a whole new face of 
addiction.  When cocaine is mixed with a base (usually ammonia or sodium 
bicarbonate) and heated it converts to its free base form, and can be smoked 
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rather than inhaled or injected.  This new form of cocaine gives a stronger and 
faster high compared to the traditional modes of cocaine usage.  Crack cocaine 
is less expensive compared to the powder form and its widespread use amongst 
the poor and homeless further entrenched the problem in this society [9]. 
The latest statistics provided by the National Institute of Drug Abuse 
website show a steady number of people using cocaine in this society over the 
last several decades.  In the ‘Monitoring The Future’ study, performed at the 
University of Michigan on public high school children who voluntarily report illicit 
drug use, almost 30,000 8th grade students (~0.5%) during the 2015 academic 
year reported using cocaine in the month prior to the study.  Respondents who 
reported using cocaine within the last month are classified as the group most 
likely to be addicted to cocaine.  The number of students using cocaine during 
the same period increases to over 58,000 students by the 12th grade (~1.1% of 
all 12th graders nationally) [10]. 
The Monitoring The Future study has been conducted annually since 
1975, and reveals that the percentage of students using cocaine has remained 
steady for years [10].  To address the larger point, there is a steady number of 
teenaged students who continue to seek out this drug.   
Looking at the US population as a whole, a 2012 study conducted by the 
Substance Abuse And Mental Health Administration (SAMHA) found that over 
1.5 million people, aged 12 and over, used cocaine during the month prior to the 
study.  Over 39 million people in the same age group reported using cocaine at 
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least once in their lifetime where men are almost twice as likely as women to use 
cocaine in any form [11]. 
In 2013, the US government dedicated almost 24 billion dollars on its 
attempt to control drug use, ranging from treatment and prevention strategies to 
law enforcement and incarceration for illicit drug use.  This amount has climbed 
to over 30 billion dollars in 2016 [12]. Though this money is primarily focused on 
dealing with the opiate abuse epidemic in this country, the statistics in the 
previous paragraphs demonstrate the continued need for drug treatment for 
cocaine addiction and abuse.    
Since its discovery, cocaine consumption has evolved to have several 
routes of administration - from chewing the leaves, to inhaling the isolated 
compound, to smoking the free base form.  The magnitude of its effect on the 
body is directly correlated to the concentration that is ingested.  This drug has 
multiple effects on the body, acting on both the brain and the periphery.   
 
Cocaine pharmacology –  
The sites of action of cocaine are complex due to it binding at several 
targets in the body based on the local concentration of the drug ranging from ion 
channels to monoamine transporters.  At lower concentrations cocaine binds to 
voltage-gated Na+ channels, blockage of sodium currents in neurons and thus 
yielding a local anesthetic effect [13].  At higher concentrations, cocaine can 
inhibit Na+-dependent monoamine transporters for dopamine, serotonin, and 
norepinephrine, resulting in sustained high neurotransmitter levels in the synaptic 
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cleft [14-17].  The reinforcing effects of cocaine are believed to work primarily 
through the dopaminergic stimulation, but there are several other physiological 
effects as well.   
 
Ion channel blockade –  
Cocaine has been reported to modulate the activity of several voltage-
dependent cation channels on neurons, namely sodium, potassium and calcium 
[18].  Each blockade produces a different physiological response, but the most 
pronounced is that of the sodium blockade that imparts cocaines local anesthetic 
activity.  Interestingly, researchers have found that cocaine can block sodium 
channels in several of their recognized conformations:  resting, open, or active, 
unlike most sodium channel modulators that bind and stabilize specific 
conformations[19].  Although cocaine can bind sodium channels in various 
conformational states, it prefers the inactive conformation (with resting requiring 
the highest concentration with a Ki of 328 µM, and the active and inactive states 
being inhibited at 19 and 8 µM, respectively) [13]. Indeed, binding and 
stabilization of the inactive state of the channel leads to channel blockade and in 
heart leads to cardiac arrest, the major toxic effect of acute cocaine overdose  
[19].   
Cocaine has the opposite effect at calcium channels.  At pharmacological 
doses, cocaine enhances calcium current by increasing the channel opening and 





Monoamine re-uptake inhibitor 
Most of the behavioral effects of cocaine derive from its potency at the 
sodium-dependent family of monoamine transporters, the primary mechanism of 
neurotransmitter removal in synaptic termini within the mesocorticolimbic system.  
Each of the monoamine transporters targeted by cocaine - dopamine (DAT), 
serotonin (SERT), and norepinephrine (NET) are responsible for removing the 
specific monoaminergic neurotransmitter from the synapse back in to the 
presynaptic neuron, arresting signaling at the postsynaptic neuron and maintain 
proper tone throughout the nerve.  The main transporter responsible for 
cocaine’s euphoric properties is DAT; however, its ability to block re-uptake of 
serotonin and norepinephrine is well established[15, 17, 21-23]  
 
SERT – Cocaine inhibition of SERT has a combination of effects that lead 
to both the rewarding and aversive aspects of cocaine use [24].  Though 
cocaine’s effect on SERT is not completely understood, rodent knockout models 
of the serotonin transporter show altered responses to cocaine compared to wild-
type animals [25].  More specifically, SERT-/- mice display delayed hyperactivity 
after cocaine treatment compared to wild type mice, while the same cohort of 
mice show enhanced conditioned place preference (CPP) compared to WT mice.  
Taken together, the researchers suggest that cocaine action at SERT contributes 
to the anxiety and nervousness that accompanies the euphoria of the cocaine 
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high [26].  The significance of these data, however,  are in question as the same 
group of researchers was unable to repeat the CPP results in SERT KO mice in 
another study [27].  
 
NET – The potency of cocaine at the NET was demonstrated by 
transfecting HeLa cells with a functional mutant form of NET.  The transporter 
could perform its role in NE reuptake, and still be bound by certain psychoactive 
substances previously shown to bind to NET.   This triple mutant (NET:F101C-
A105G-N153T) displayed the greatest loss of sensitivity to cocaine treatment 
compared to the other drugs in the experiment seen as a rightward shift in the 
dose response curve (>1.5 orders of concentration) [28].  The behavioral effect of 
cocaine through action at NET was demonstrated through NET KO mice. The 
NET-deficient mice showed hypersensitivity to cocaine treatment compared to 
WT controls.  When NET KO mice receive cocaine treatment, they display 
increased levels of activity compared to WT mice.  Prior to being given cocaine, 
the NET KO mice showed less activity compared to WT controls [29].  These 
results suggest that NET plays a role in cocaine addiction, but due to expression 
of NET in the body, the overall influence NET is believed to affect the cardiac and 
circulatory response to cocaine.   
 
DAT – The rewarding effects of cocaine arise primarily through the 
mesocorticolimbic dopamine (DA) system, making the DAT a strong candidate 
target for the behavioral actions of cocaine .  This circuitry is composed of DA 
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neurons originating in the ventral tegmental area (VTA) of the brain and 
extending into the nucleus accumbens (NAc), amygdala and prefrontal cortex 
(PFC) [18, 30]. DAT blockage by cocaine and ensuing increases in dopamine 
concentration within the synapse produces feelings of euphoria.  By repeatedly 
subjecting the synapse to higher dopamine levels, whether voluntary or not, the 
dopaminergic tone is reinforced and the animal becomes conditioned to the 
altered level of synaptic dopamine [18].  Such conditioning reinforces (cocaine) 
seeking behavior that defines the addictive state.  
Although DAT is thought to be the primary target of cocaine that leads to 
reinforcing behavior in addiction, ablation of the transporter does not completely 
curb cocaine cravings as seen in work with DAT KO mice.  After genetically 
removing the dopamine transporter in C57Bl6 mice, researchers found that the 
mice could still be trained to self-administer cocaine, suggesting that other 
transporters may also be involved [23].  The promiscuity of what is often referred 
to as a “dirty drug”,  through binding several partners ranging from transporters to 
ion channels, make treating cocaine addiction extremely challenging.  From small 
molecules to entire multimeric protein complexes, the current state of cocaine 
addiction treatments encompasses a plethora of molecules.  Each treatment 
focusese on either pharmacokinetic or pharmacodynamic approaches, since this 
section dealt with PD treatments, the next section will focus on PK based 





Cocaine metabolism –  
 Several enzymes can breakdown cocaine once it is distributed throughout 
the blood.  Human liver carboxyl esterase will convert cocaine into 
benzoylecgonine through demethylation of the methylester at the 2 position on 
the tropane ring.  This enzyme can also perform a transesterification of cocaine 
into the toxic metabolite cocaethylene when ethanol is also present in the blood. 
[31, 32]  Cytochrome P450 processing by CYP 3A4 produces norcocaine through 
demethylation at the nitrogern on tropane.  The majority of cocaine metabolism 
occurs by human butyrylcholinesterase (hBChE).  [33]  Through hydrolysis of the 
esterbond connecting the tropane ring to benzoate, BChE produces ecgonine 
methyl ester and benzoic acid.   
Though cocaine can be processed into several different metabolites 
depending on which enzyme it binds, the fate of the product can be more toxic 
than cocaine itself.  As mentioned above, the combination of cocaine and ethanol 
can produce cocaethylene that has previously been shown to pose risk to nerve 
and cardiac cell functioning, as well as, being an immune suppressant. [34, 35]  
Methylecgonidine can be produced when cocaine is ingested as its free-base 
form, crack cocaine.  This toxic metabolite has shown to be detrimental to 
smooth muscle functioning in the respiratory tract.  [36, 37]  Due to the toxicity of 
certain cocaine metabolites, it is crucial to not only to clear cocaine after 
ingestion, but avoiding generation of the toxic metabolites is also important in 
metabolizing this drug.   
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Treatment for cocaine addiction –  
Two distinct approaches to treating cocaine addiction currently exist.  The 
first, and most commonly used, approach involves correcting the addict’s 
behavior by reconditioning them to seek constructive hobbies and pastimes when 
the urge to use cocaine arises.  Since the behavioral reconditioning approach 
involves a non-pharmacological method to treat cocaine, it will not be considered 
further in this thesis.  While only pharmacologically based addiction treatments 
will be explored, it is important to note that the effective treatment of cocaine 
addiction will likely involved the combined use of therapeutics and behavioral 
reconditioning.  The pharmaceutically based treatments can be divided into small 
molecule therapies that target specific receptors to interfere with cocaine’s ability 
to bind or its effect after binding, and protein-based therapies that can either 
sequester or metabolize cocaine in the peripheral circulatory system.   
 
Small Molecule therapies  
Due to cocaine’s ability to bind monoamine transporters, a multitude of 
drugs have been developed to either interfere with the reuptake inhibition or 
correct the altered tone of a specific neurotransmitter pathway.  This 
pharmacodynamic approach focuses primarily on preventing the body’s response 
to cocaine either by simply inhibiting cocaine binding to its sites of action or by 
altering neurotransmitter function (mainly dopamine) that leads to reinforcement.  
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The following list of molecules is not meant to be exhaustive, but more to give an 
overview of the field’s diversity.   
 
L-Dopa: Since the euphoric feelings of cocaine are primarily attributed to the 
change in dopaminergic tone, correcting this alteration has a considerable 
amount of attention in the efforts to develop a drug to treat cocaine addiction.  
Levodopa (L-Dopa)-carbidopa combination therapy has been proposed in order 
to treat the dopamine deficiency seen in long-term cocaine addicts.  L-dopa is 
converted to dopamine in DA neurons,  a process that is enhanced through 
carbidopa’s capacity to decrease L-dopa metabolism.  Treatment with dopamine 
precursors (L-dopa), was therefore thought to reverse the hypdopaminergia in 
addicts [30]. Unfortunately, this approach showed no clinical efficacy compared 
to placebo in a double-blind, randomized, human clinical trials, and was not 
pursued further [38]. 
 
Dextroamphetamine (D-AMPH):  D-AMPH can also correct hypodopaminergia 
with the added effect of decreasing post-synaptic dopamine D2 receptor (D2DR) 
activity where enhanced binding of DA at D2DR is seen in chronic cocaine users 
[39].  Like cocaine, D-AMPH acts at DAT and inhibits reuptake of DA and 
increases synaptic DA levels.  D-AMPH also efficiently binds the other 
monoamine transporters, in addition to vesicular transporters as well as trace 
amine receptors[40].  Other transporter inhibitors that display higher selectivity 
for DAT over SERT or NET have been shown to correct hypodopaminergia, but 
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have not proven effective due to abuse liability since their overall physiologic 
effect mimics that of cocaine itself [39, 41, 42] 
 
Doxazosin: Doxazosin is a long-acting, selective alpha-1 adrenergic antagonist 
that reduces central NE activity.  This molecule will limit the behavioral effects of 
cocaine and attenuates cocaine-induced reinstatement of cocaine seeking 
behavior in rats [43, 44].  Though this drug shows promise, it suffers one of the 
most common problems associated issues with small molecule therapies, 
compliance.  Each drug has to be taken willingly by the addict, and failure to take 
the drugs to curb addiction often result relapse into cocaine seeking behavior.  
Disulfiram (Antabuse):  Disulfiram is a copper chelator that is mostly associated 
with treatment of alcohol addiction through inhibiting acetaldehyde 
dehydrogenase, the enzyme that converts alcohol metabolite acetaldehyde to 
acetic acid.  Disulfiram also inhibits dopamine-beta-hydroxylase (DβH), an 
enzyme in the DA synthesis pathway. Disulfiram administration reduces NE 
levels in the brain that, in turn, reduces stimulation of α1A-adrenoceptors.  
Reduction of NE tone results in modulation of cocaine reinforcement and 
decreased cocaine use [45-47].  Unfortunately, more recent studies showed 
mixed results where some cohorts treated with disulfiram had no better 
adherence to abstinence versus placebo [46]. 
Nepicastat:  Another NE altering drug, Nepicastat (SYN 117), is a selective DβH 
inhibitor.  This drug attenuates reinstatement of cocaine-seeking behaviors in 
rats following exposure to several reinstatement protocols, namely – cocaine-
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related cues, food prompts, and stress [48].  Oddly enough, this drug showed 
efficacy in rats but not in squirrel monkeys and the effects of SYN 117 in humans 
is mixed[49].  While it is capable of attenuating the subjective effects of cocaine, 
it does not curb craving behavior[50].  
 
Modafinil:  Modafinil, another DAT and NET antagonist, increases extracellular 
glutamate, and decreases cocaine reward and reinstatement [51-53]. In a head-
to-head comparison with two other therapeutic approaches, L-dopa/carbidopa 
and naltrexone, modafinil failed to show a significant decrease in cocaine use 
compared to controls or between groups [54]. 
Topiramate: The gamma amino butyric acid (GABA) pathway is involved in 
decreasing the tone of several neurotransmitters that fluctuate after cocaine use.  
Topiramate, a GABAa receptor agonist, effectively reduced cocaine craving and 
use in humans [55-57].  Similarly, vigabatrin, an irreversible GABA 
aminotransferase inhibitor, showed an ability to inhibit cocaine-induced increases 
in nucleus accumbens in rats [58, 59].  These approaches have shown the most 
promise among the small molecule therapeutics.  
 
Others:  Research into the serotonergic pathway found that serotonin receptor 
subtype 5-HT2A is involved in cocaine’s physiologic effect.  Antagonists at this 
receptor have shown attenuated cocaine-induced reinstatement of cocaine-
seeking behavior; however, the issue of complying with drug treatment has 





As promising as some of the above molecules may be, the limitations of 
therapeutic compounds stem from abuse liability and compliance with treatment 
[30].  As small molecule therapeutics continue to be investigated, another 
approach to treating cocaine addiction has come to the forefront of the addiction 
treatment genre.  Biologically derived therapeutics have gained much interest 
due to their ability to be produced without multiple synthesis steps, production 
yield, and ability to alleviate compliance issues due to persistence in circulation.   
The application of biologics to address cocaine addiction focuses not on 
the capacity to directly alter the pharmacodynamics of cocaine, but rather to alter 
cocaine’s pharmacokinetics.  Small molecule-based therapeutic approaches that 
attempt to alter the pharmacodynamics of cocaine face the challenges reversing 
or altering the activity of many of cocaine’s molecular targets.   The difficultly in 
dealing with the  ‘dirty drug’ properties of cocaine in itself has complicated the 
therapeutic approaches have thus yielded limited effectiveness in treating this 
complicated disease in humans.   The focus on altering the pharmacokinetics of 
cocaine, either through antibody or vaccine-mediated chelation or by accelerating 




Vaccine:  A cocaine vaccine (TA-CD) was developed that contains a cocaine 
hapten conjugated to inactivated cholera toxin B [61].  This antibody based 
therapeutic generates an immunologic response that sequesters or chelates 
cocaine in the circulating periphery.  The cocaine is then cleared by endogenous 
esterases in circulation and then by renal elimination.  Though this approach 
initially showed promise in correcting addictive behavior in lab rats, this strategy 
is overcome by ingesting larger quantities of cocaine [62]. 
 
Enzyme-based metabolism:  
Monoclonal 15A10:  A cocaine-hydrolyzing monoclonal antibody – 15A10 –
displayed the capacity to bind and hydrolyze cocaine to inactive metabolites 
benzoic acid and ecgonine methylester, the same metabolites that the 
endogenous enzyme, butyrylcholinesterase, produces.    Administration of 15A10 
effectively suppressed cocaine self-administration in a rodent model [63, 64]. 
15A10 was also capable of attenuating the increase in mean arterial pressure 
(MAP) in response to cocaine injection, suggesting that the catalytic antibody 
may also be used as an antidote for cocaine toxicity [65].  Unfortunately the 
catalytic properties of 15A10 were poor, owing to the slow off-rate of enzyme 
products (ecgonine methyl ester and benzoic acid) from 15A10.   In this 
paradigm 15A10 behaved as both an enzyme to accelerate cocaine metabolism 
but also, effectively as a cocaine chelator making the stoichiometry of 
cocaine:antibody a limitation.  Like vaccine treatment the effect of 15A10 was 
surmountable with higher concentrations (or doses) of cocaine.  Due to this 
21	  
inability to process cocaine efficiently, this approach was deemed not viable as a 
therapeutic for cocaine addiction [66]. 
 
Butyrylcholine esterase:  Butyrylcholine esterase (BChE), the enzyme that 
breaks down the majority of cocaine in circulation, has been extensively pursued 
as a potential therapeutic[67, 68].  The initial hurdle for this enzyme stems from 
its poor kinetics for the active sterioisomer of cocaine,  (-)-cocaine (~ 4 moles of 
cocaine per minute).  Through several mutagenesis approaches the selectivity 
for the (-) enantiomer over the inactive (+) enantiomer was substantially 
improved, as well as improvements in the catalytic properties of the enzyme.  As 
with many protein-based therapeutics, and perhaps more apparent with BChE, 
the protein itself is extremely difficult to produce in large quantities in a cost-
effective manner.  In addition, increases in BChE activity is linked to 
neurodegenerative disorders and the toxicity of Beta-amyloid production [69, 70].   
Although more efficient BChE mutants have recently been developed as 
recombinant molecules with long-term viability, the over-reaching limitation of this 
enzyme, however, stems from the potential for an immune response directed at 
the host BChE due to mutations in the BChE protein in circulation [33]. The 
potential to develop an autoimmune response against host BChE may ultimately 
limit the usefulness of this biologic in human subjects.   
 
Cocaine Esterase – Evolution, discovery, and development into human 
therapeutic 
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While searching for a protein to develop into a biosensor for detecting 
trace amounts of illicit drugs, a group from the University of Cambridge, England 
stumbled upon a cocaine-hydrolyzing enzyme during a genetic screen of various 
bacteria [71].  The enzyme, cocaine esterase (CocE), is expressed in the 
bacterium Rhodococcus MB1.  These particular bacteria grow in the soil 
surrounding the roots of the Erythrozylon coca plant, and have evolved to use 
cocaine as a nitrogen and carbon source after the initial breakdown of cocaine by 
the cocaine esterase enzyme.  Once the gene encoding CocE was isolated and 
cloned, the initial studies determined the kinetic profile of the enzyme [71].  The 
first expression of CocE was performed in E. coli, and the soluble protein was 
purified using affinity chromatography.    
The purified CocE gene product effectively hydrolyzed cocaine, with a KM 
of 1.3 +/- 0.085 µM for cocaine based on HPLC analysis [71].  Subsequent 
studies determined the kinetic constants of cocaine hydrolysis by CocE to be a 
kcat of 470 min-1 and KM of 640 nM [72].  This exceptionally high activity toward 
cocaine is approximately 800-fold higher than the activity of wildtype, 
endogenous BChE.    The actual kinetics of CocE have been a point of 
contention throughout in the recent literature and has partially focused on the 
different assays utilized to assess the enzymatic reaction.   These two initial 
reports have a discrepancy of about 4 orders of magnitude.  A major difference in 
the described values relates to the integrity or stability of the enzyme itself.  As 
described below, wildtype CocE is extremely labile at higher temperatures 
making measurement of enzymatic activity more challenging. In our laboratory, 
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we have commonly found that freshly prepared wildtype CocE has a KM for 
cocaine of about 25 µM with a Vmax of about 2500 min-1.  Outside of the 
differences in kinetics found by experimentation and enzyme stability (see 
below), CocE has proven to be the most efficient naturally occurring enzyme able 
to hydrolyze cocaine. 
Structural analysis of CocE by x-ray crystallography suggests that the 
enzyme is a member of the α/β hydrolase superfamily of proteins.  It has three 
domains in its overall structure – Domain I is the α/β hydrolase fold, Domain II 
contains seven helices, and Domain III has a jelly roll structure[72].   The 
Figure 1-2:  Structure of cocaine esterase.  The 
three domains of the CocE monomer are shown in 
yellow (Domain I), blue (Domain II) and green 
(Domain III).   The catalytic triad is shown in red 
sticks. 
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catalytic triad is sandwiched in between the three domains and helix 2 and 3 of 
Domain II, which form a lid over the triad with their antiparallel orientation.  The 
protein is functional as a dimer, although initial reports claimed that the protein 
exists as a 65 kDa monomer[71, 73]. 
 
 The kinetics and production of CocE provide evidence of its potential as a 
therapeutic candidate for treating cocaine addiction. The recombinant CocE 
molecule can be expressed as a soluble protein in E. coli, reaching yields of 100-
200 mg/ml in shake flask cultures.  Scaling-up to small fermentation formats (i.e. 
10 L) yield of reaching 2-3 g/L can be easily obtained.   This is in sharp contrast 
to the production of recombinant BChE that must be expressed in insect cells 
cultures (1 mg / L of culture ) [74] or in goats milk (0.1 – 5 g / L) [75], the latter 
requiring the production of a transgenic goat expressing BChE mutants. The 
superior catalytic properties of CocE and the lower potential to elicit an 
autoimmune response to this bacterial protein, coupled with the facile production 
and purification of the enzyme make CocE a far more attractive candidate than 
BChE. 
 
Thermostability of CocE 
Though CocE is a relatively efficient enzyme at hydrolyzing cocaine our 
laboratory in collaboration with Dr. James Woods (University of Michigan) and 
Donald Landry (Columbia University) performed the initial in vitro activity assay 
with WT CocE and found it has a half-life of about 12 minutes at 37°C in 
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phosphate buffered saline (PBS) [76].  This thermolability thus presented 
significant setbacks to the development of CocE in in vivo studies and for it to be 
considered for use as a therapeutic in humans.  We also demonstrated the 
capacity of CocE to protect rats against a lethal dose of cocaine (180mg / kg), 
and found the enzyme only showed a protective advantage immediately after 
CocE administration [77].  We subsequently determined that the enzyme’s in vivo 
half-life was approximately 12 minutes [76].  
In an attempt to improve the thermostability of CocE our laboratory in 
collaboration with Dr. Changuo Zhan (University of Kentucky) utilized 
computational approaches using available x-ray crystallographic data [76].  This 
analysis demonstrated that the two helices in Domain II conferred the instability 
of this protein.  Following a survey of residues in Domain II by site-directed 
mutagenesis, we focused on three residues (L169, T172 and G173) and that when 
mutated displayed significant thermal stability.   Combining mutations T172R, 
and G173Q produced an enzyme (RQ-CocE) with a τ1/2 at 37°C of approximately 
5.5 hours, using an in vitro assay in PBS [76].  Similar time courses were 
observed using the in vivo, protection against cocaine-induced lethality assays.   
The improvement in τ1/2 at 37°C was approximately 25-27-fold raising the 
potential of this protein-based therapeutic for the treatment of cocaine addiction 
and overdose.    
While developing the thermostable mutants we further determined that 
CocE is a dimer, based on size-exclusion column (SEC), as well as x-ray 
crystallography [78].  We determined that the major dimer interface was located 
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at enzymes extreme N-termini where beta-strands from each protomer interacted 
in an anti-parallel fashion and together completed a beta sheet spanning both 
monomers (Figure 1.3).  To stabilize this interface we generated mutant mutants 
containing two cysteine residues (S4C & S10C) at the N-terminus of each protein, 
engineered to form two disulfide bonds spanning the dimer interface and 
effectively crosslinking the two monomers together (CC-CocE).  This new 




To further enhance the thermostability of CocE, we combined the CC-
CocE and the RQ-CocE mutants to generate CCRQ (S4C/S10C/T172R/G172Q-
CocE).  Combining these mutations provided an unprecedented level of stability 
at 37°C of over 40 days in saline buffer, and representing an almost 5000-fold 
improvement over the wild-type enzyme .  The sustained duration of in vitro 
Figure 1.3:  CocE’s quaterinary structure and dimer 
interface  Left panel shows the dimer form of CocE with 
monomers facing each other.  Right panel - Alignment of 
CocE’s N-termini.  The antiparallel beta strands were 
mutated to cysteine and Fo-Fc electron density 
demonstrates that thiol groups in opposite strands lie in 
close enough proximity to form disulfide bonds between 
the two monomers[1].  (taken from Narasimnhan et al, 
2011)   
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activity of CCRQ at 37°C prompted the in vivo studies in various rodent 
paradigms.  The initial studies with CCRQ showed the same level of protection 
that was observed in earlier CocE studies, where protection against a lethal dose 
of cocaine was seen immediately after administration but unfortunately no 
protection was seen after 24-hours of administration [1, 79].  
 To extend the in vivo residency of CocE our laboratory, in collaboration 
with Dr. Victor Yang (University of Michigan) reported that covalent modification 
of CocE with polyethylene glycol polymers afforded enhanced activity in vivo [80].   
We subsequently determined that covalent attachment of PEG (PEGylation) onto 
CCRQ provided protection of rodents against lethal doses of cocaine for 48 
hours post CocE administration using two rodent models of protection against 
cocaine-induced lethality (Figure 1.4, [1])  
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These exciting data prompted more thorough analysis of the PEGylation 
of CocE and the effect on in vivo life-time.   This analysis is the subject of the first 
Specific Aim of this thesis work.  For CocE is to be used as a viable human 
therapeutic for cocaine addiction, it will require full in vivo activity sustained for as 
many days as possible, to provide the most efficient dosing regimens, minimize 
compliance issues and reduce production costs. 
 
The kinetics of cocaine hydrolysis by CocE 
While developing the thermostable CocE, one combination of point 
mutations (L169K, G173Q-CocE, or  KQ-CocE) hydrolyzed cocaine two to three 
times faster than wildtype and the other thermostable mutant, RQ-CocE 
Figure 1.4:  Survival curves comparing the in vivo 
results of CCRQ-CocE compared to PEG-CCRQ-
CocE.  No protection against a lethal dose of cocaine 
(180 mg/kg) were shown in mice or rats dosed with 
CCRQ-CocE.  All rodents were protected from the 
same lethal dose of cocaine for 48 hours after 
administration of PEG-CCRQ.   
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(Vmax~6500 min-1 for KQ-CocE versus 2500 min-1 for RQ-CocE) [81].  We 
interpret the increase in thermostability to the Nζ atom of K169 where new 
hydrogen bonding partners with active site waters and new van der Wals 
interactions with the hydroxyl of Y44 are formed which together stabilize the two 
helices in DOM2.  Combined with G173Q there is an overall improvemt in 
thermostability and an accompanying increase in Vmax through allowing for 
faster product release and therefore a higher maximal velocity.  While this 
interpretation explains the enhanced Vmax of KQ-CocE, it does not provide an 
explanation for the increase in KM for substrate cocaine.   
The enhanced Vmax of KQ-CocE demonstrated that a more efficient 
enzyme could be engineered and inspired a more rational structure-based 
approach to construct a form of the enzyme with even higher catalytic activity.  In 
trying to develop CocE into a potential therapeutic for cocaine abuse, having the 
most efficient enzyme possible would be highly desirable in order to reduce the 
dose needed.  To that end, we formulated an interrogation of the enzymes active 
site, assessing the contributions of residues that interact directly with the cocaine 
substrate.  Our goal is to enhance the affinity of the substrate (lower the KM) or 
increase catalysis (Kcat, or Vmax) by optimizing the chemistry of catalysis and/or 
through increasing product release.  
Early crystallographic analysis of CocE by Larson and coworkers found 
electron density in the active site that at the time was modeled as a benzoic acid 
partial product [72].  Both the high resolution of the structure (1.6Å) and the 
coordination of this molecule by several aromatic residues suggested that this 
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density was indeed benzoic acid.  Together with the structure of CocE bound to a 
transition-state analogue (phenylboronic acid), an approximation of the active 
site, and potentially the substrate-binding site, could be made.   While these two 
structures were informative, it does not quite help us to place the tropane ring of 
cocaine, arguably the most important moiety that contributes to substrate 
specificity.  Moreover, analysis of the active site reveals a rather large binding 
pocket that could either accommodate substrates that are considerably larger 
than cocaine, or alternatively serve as a docking site for cocaine or cocaine-like 
molecules to bind and transition toward the active site where hydrolysis occurs. 
Toward attaining a better understanding the nature of the actual binding 
site for cocaine we endeavored to generate a high resolution data set and model 
of CocE bound to non-hydrolyzable cocaine-like molecules.  The two 
compounds, WIN 35065-2 and RTI-150, both contain methylated tropane rings 
like cocaine, both bind and inhibit DAT, and also behave like cocaine in self-
administration models of addiction [82, 83].   In addition we attempted to utilize 
catalytically compromised mutants of CocE to see if we could trap cocaine bound 
to the active site(s).  Once validated these structures would be extremely 
valuable for not only delineating the catalytic mechanism of this enzyme but also 
useful in engineering more catalytically active mutants.   
In an attempt to find which residues lay in close enough proximity to the 
cocaine substrate, we reasoned that a crystallographic image of either cocaine 
analog bound in the active site would provide this information.  After obtaining 
data sets with either analog bound, and generating a structural models of the 
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compounds bound to CocE we proceeded to first validate the model by site-
directed mutagenesis and then, based on this model identify, several residues 
that may enhance the enzymes catalytic properties.   
We were also fortunate to obtain a high resolution data set of a 
catalytically impaired mutant CocE (D259N) bound not to substrate cocaine but as 
a transition state bound as a covalent intermediate to the catalytic serine S117.  
This real intermediate, as opposed to the previously reported transition-state 
mimic, phenylboronic acid, reveals a significantly different microenvironment 
around the active site.  Using these data we were able to obtain a nice model for 
the catalytic mechanism of CocE and test this by mutagenesis.  Moreover, these 
data, together with the cocaine analog structures have directed further 
mutagenesis studies with the goal of engineering a better enzyme. 
 The crystallography, biochemistry, and enzymology with the goal of 






Specific Aim 1:  Extending the in vivo enzymatic activity of CocE via PEGylation 
 Due to the short in vivo half-life of CocE, covalent attachment of 
polyethylene glycol (PEG) polymers was performed and shown to extend the 
duration of in vivo protection against cocaine-induced lethality (<24 hours 
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compared to ~48 hours, with PEG).  By first ascertaining the location of what 
turned out to be a single site of attachment attempts to further extend the in vivo 
activity by adding additional PEGs were successfully performed.  Through 
utilizing a structure-based strategy for targeting specific residues with PEG 
polymers, we were able to produce mutants displaying longer in vivo enzymatic 
activity.   
 
Specific Aim 2:  Active site analysis of CocE using non-hydrolysable cocaine 
analogs and active site mutants 
One of the major goals of research on cocaine esterase as a potential 
therapeutic for cocaine addiction is to enhance the catalytic efficiency of the 
enzyme itself.  Our observation that one thermostable mutant, KQ-CocE, has a 
Vmax that is three times the velocity of our other CocE mutants has inspired us to 
propose that the catalytic capacity of CocE may be tuned.  Structural analysis of 
the residues within the “binding pocket” that contains the active site triad, provide 
hints about the location of substrate binding.   Though we do not have a structure 
of cocaine bound in the active site, we have procured two different non-
hydrolysable cocaine analogs (WIN 35065-2 and RTI-150) and delineated their 
structures bound to CocE.  To validate this structural model mutations were 
made at the analog-protein interface and tested for their capacity to alter the 
catalytic efficient of CocE on cocaine.  Using the validated model of the cocaine 
analog-bound CocE we designed new mutants with the intention of altering 
(enhancing) the interaction between enzyme and substrate/product with the 
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hopes of generating a more efficient enzyme.  Since the two cocaine analogs are 
non-hydrolyzable, they serve as inhibitors of CocE.  This aim also analyzes the 
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 Cocaine addiction remains prevalent in today’s society.  According to 
current statistics, around 1.6 million people in the United States fit the criteria of a 
cocaine addict[1].  To compound this problem, one in one hundred teenagers fit 
the classification of a cocaine addict.  According to the Monitoring the Future 
Study, conducted in 2014, almost 30,000 students in the 8th grade reported using 
some form of cocaine in the last month, with the number increasing to over 
58,000 for 12th grade students [2].  More urgently, there was a 42% increase in 
the number of cocaine related deaths between 2001 and 2014.  Approaches to 
treat cocaine addiction have been developed over the last several decades; 
however, none have proven successful as seen through the prevalence of 
addiction. Cocaine antagonists at two of its major sites of action, the dopamine 
transporter and the voltage-dependent Na+-channel, unfortunately displayed 
similar efficacy as cocaine and both blocked the channel and the transporter[3, 
4].  Anti-cocaine antibodies (catalytic and non-catalytic) and vaccines have 
represented attractive avenues to reverse cocaine’s bioavailability in vivo but 
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unfortunately proved to be surmountable by higher doses of cocaine [5].  
Alternatively, we and others have taken a protein-based enzymatic approach to 
modify the pharmacokinetics of cocaine and accelerate its metabolism to inactive 
metabolites benzoic acid and ecgonine methyl ester (Reviewed in [6]). In vivo 
studies in rodents with CocE suggested that it could protect against cocaine-
induced cardiovascular, respiratory and CNS effects, and even lethality [7-9].  
Despite the effectiveness of WT-CocE the enzyme is thermolabile with a t1/2 ~15 
min at 37C, limiting its full potential as a therapeutic [8]. 
To circumvent the thermostability issues we first incorporated a protein 
structure-based approach to identify regions of thermolability and successfully 
generated a thermostable mutant (known as RQ-CocE) that retained its 
endogenous enzymatic activity at 37°C in assay buffer [8].The thermostable form 
not only protects against cocaine-induced cardiovascular and respiratory effects 
that lead to lethality but can diminishes self-administration of cocaine in both 
primate and rodent models [9-11]. In addition, RQ-CocE is capable of rescuing 
rodents pre-administered with otherwise toxic doses of cocaine suggesting that 
the enzyme has therapeutic potential for cocaine overdose. CocE was also 
tested for its capacity to restore cardiovascular function following cocaine-
administration in rhesus monkeys [12].  More recent positron emission 
tomography studies using labeled cocaine suggest that systemically 
administered CocE can accelerate the removal of cocaine from the CNS [13]. 
More significantly, CocE has been tested in humans for its capacity to 
accelerate cocaine removal supporting CocE’s potential as an antidote for 
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cocaine overdose/toxicity [14].  In these extremely encouraging Phase II clinical 
trials RQ-CocE accelerated the reduction of systemic cocaine levels nearly 
10,000-fold faster than vehicle. We look forward to seeing RQ-CocE advance to 
Phase III trials. 
We also determined that CocE forms a symmetrical dimer and determined 
that dimer disruption leads to protein aggregation and enzyme inactivation.  
Using x-ray crystallography we delineated the dimeric nature of the enzyme and 
the dimer interface.  Through the strategic incorporation of cysteine residues on 
the amino terminus on each protomer, the major participant of the dimer 
interface, we engineered two disulfide bridges spanning the interface.  The 
crosslinked dimer (known as CC-CocE) exhibited superior thermal stability in in 
vitro assays (t1/2~12 hours at 37°C) [15]. Through combining both RQ-CocE and 
CC-CocE mutants, we constructed the most thermostable CocE mutant to date, 
CCRQ-CocE, which retains full in vitro enzymatic activity for over 40 days after 
incubation at 37°C in buffered saline [15].  
More recently we demonstrated that CCRQ-CocE potently abrogates 
cocaine self-administration, a model cocaine addiction and drug seeking 
behavior in rats, supporting its potential as a treatment for cocaine [12].  
Suppression of self-administration along with behavioral therapy could represent 
a major breakthrough in treatment of cocaine addiction. 
Our initial studies in rodents with CCRQ-CocE found that its in vivo activity 
disappears in less than 24 hours. Modification of CocE with branched 
polyethylene conjugates of maleimide (PEGylation) extended this t1/2 to greater 
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than 48hrs in both rat and mouse models [15].  In this current study we have 
ascertained the location of the surface cysteine residues that are PEGylated and, 
with the aid of high-resolution structural models of CocE, hypothesize that current 
PEGylation strategies cover only a portion of the enzyme.  Incomplete PEG 
coverage would have less than optimal ‘stealth’ properties and be more 
susceptible to immune surveillance and/or proteolysis.  In this chapter, we 
describe the use of structural information on CocE to guide the strategic 
placement and number of PEG moieties on CocE and its enhanced effect on t1/2 
in rodents.  
 Early studies with CCRQ-CocE suggested that the enzyme’s in vivo 
activity disappears within 24 hours.  To extend the in vivo residency time we 
incorporated a stealth approach to elude immune surveillance or proteolysis, 
utilizing covalent modification of CocE with polyethylene glycol (PEG) polymers. 
PEGylation of RQ CocE does not inhibit the enzymatic activity and protects 
against cocaine toxicity as effectively as un-PEGylated CocE [16].  Due to the 
relative instability of RQ-CocE, we then pursued PEGylation of CCRQ-CocE 
since this is the most stable form of CocE to date.  Our initial study found that 
PEG:CCRQ-CocE protects rodents against a lethal dose of cocaine for up to 48 
hours [15].  In this current study we assess whether PEGylation of CocE could be 
enhanced and whether the enhancement yields an extended in vivo residency 
time.   The key questions that we aim to answer in the current study are:  1) 
Where is CocE being PEGylated?,  2)  Does adding more PEG molecules per 
monomer of CocE prolong in vivo activity? and 3) How does the size and shape 
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of PEG effect the protection of CocE in vivo? We utilize site-directed 
mutagenesis to map the PEGylation and combine analysis of the enzyme’s 





Generation of CocE point-mutants:  Oligonucleotides (IDT, San Diego, CA) 
were designed based on the crystal structure of CCRQ-CocE [15] and used in a 
modified Quickchange™ protocol (Stratagene, La Jolla, CA) to replace a specific 
codons in the CocE nucleotide sequence (Oligo sequences listed in Table 1 of 
the Supplemental data section).  We utilized bacterial expression vectors 
(pET23) containing the currently most thermostable mutant of CocE, CCRQ-
CocE, as a template for the mutagenesis studies [15].  The expressed protein 
has a Hisx6 tag at the amino-terminus to facilitate protein purification.  
Sequences for all mutant plasmids were confirmed by DNA sequencing. 
   
Production of CocE:  BL21 E. coli cells expressing recombinant forms of CocE 
were grown in Terrific Broth media at 37°C to an OD600 of 0.8.  Protein 
expression was induced by adding isopropyl-b-thiogalactopyranoside (IPTG) to a 
final concentration of 1 mM.  Expression was carried out at 18°C for 12-15 hours.  
At the end of induction, the cells were pelleted by centrifugation (5000 x g), 
resuspended in 50 mM Tris-HCl, pH 7.4 at 4C, 135 mM NaCl and 5 mM KCl (1 X 
45	  
TBS), supplemented with protease inhibitors (PIs) (3 mg/mL each of leupeptin 
and lima bean or soybean trypsin inhibitor).  Cells were lysed using a French 
press (Thermo Scientific) and particulate fractions were removed by 
ultracentrifugation and the supernatant, containing CCRQ-CocE mutants were 
captured using TalonTM metal chelation affinity chromatography (Clontech 
Laboratories, Inc.) and eluted with 1XTBS containing PIs and 100 mM imidazole.  
Fractions containing CCRQ-CocE mutants were subjected to oxidation using 100 
µM CuCl2 (4°C overnight) to covalently link the CocE dimer.  The oxidized protein 
was further purified using anion-exchange chromatography (Q-Sepharose) fast 
performance liquid chromatography column (GE Healthcare). CCRQ-CocE 
mutants was eluted with a 150–450 mM NaCl linear gradient in buffers containing 
50 mM Tris-HCl, pH 8.0.  The peak fractions were pooled and concentrated to 5 
mg/ml using Centricon™-30 concentrators (Millipore), and then snap frozen in 
liquid nitrogen and stored at -80°C. 
 
PEGylation of CCRQ-CocE mutants:  CCRQ-CocE mutants were dialyzed into 
1X TBS, pH 6.5 (at 4C), prior to PEGylation.  5K, 10K, 15K and 20K-branched 
polyethylene glycols (PEGs) were purchased from JenKem Inc. (JenKem 
Technology USA, Plano, TX).  PEG was added to the protein solution at 5:1 
molar excess and the reaction proceeded for 4 hr at room temperature. The 
PEG:CocE was purified on a Q-Sepharose Fast Flow column and eluted with a 
linear gradient of NaCl between 150-450 mM.  The fractions from the first elution 
peak were pooled and concentrated to 10 mg / ml prior to use.  
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SDS-PAGE analysis of PEG:CocE:  CocE mutants were resolved by SDS-
PAGE under reducing and non-reducing conditions (where noted) on a 6 % 
acrylamide gel and detected by coomassie blue staining.  
 
Activity assay of PEG:CCRQ-CocE mutants:  Purified, PEGylated CCRQ-
CocE mutants were analyzed using an UV absorbance-based cocaine hydrolysis 
assay as described previously [12].  Here, cocaine (Mallinckrodt, Hazelwood, 
MO) is added a 96-well UV-permeable plate (Costar; Corning Life Sciences, 
Lowell, MA) at 200, 100, 50, 25, 10, 5, 1 and 0.5 µM concentrations. The reaction 
is initiated by the addition of CocE (65 ng/ml, or 32.5 ng/ml final) at a 1:1 dilution 
in the plate. The velocity of the reaction was measured every 10s for 20 minutes 
by a SpectraMax Plus 384 UV plate reader (Molecular Devices, Sunnyvale, CA) 
using OFTmax Pro software (version 3.1.2).  The absorbance readings were 
converted to change in concentration of product using using Beer’s law.  The 
specific activity of the enzyme was plotted using Prism software (GraphPad 
Software Inc., San Diego, CA) and kinetics of the reaction (kcat and Km) 
generated.   
 
In vivo analysis of PEG:CCRQ-CocE:  Male wildtype NIH Swiss mice (Harlan 
Inc., Indianapolis, IN) (25-32g) were housed under the guidelines of National 
Institutes of Health according to the Guide for the Care and Use of Laboratory 
Animals (Institute of Laboratory Animal Resources, 1996).  Mice were housed 
47	  
five mice per cage and allowed ad libitum access to food and water, and they 
were maintained on a 12-h light/dark cycle.  The University Committee on the 
Use and Care of Animals (UCUCA) at the University of Michigan approved all 
experimental protocols.  In each survival study, mice were given PEG:CCRQ-
CocE at 32 mg / kg body mass via tail vein injection.  Cocaine (Mallinkrodt) was 
dissolved in 1X PBS, pH7.4 and passed through a sterile syringe prior to intra 
peritoneal administration into mice.  Purified preparations of CocE were 
administered 30 min prior to challenge with cocaine (180 mg/kg i.p. cocaine 
injection).  Animals were re-challenged with cocaine every 24 hours following the 
administration of the CocE enzyme. 
   
Results 
 
Cocaine esterase, CocE, is an alpha-beta hydrolase that effective 
metabolizes cocaine into inactive metabolites ecgonine methylester and benzoic 
acid.  We have previously demonstrated the effectiveness of CocE to reduce the 
dangerous cardiovascular and neurological effects of administered cocaine [17, 
18].  Indeed, administration of CocE not only rescues rodents from lethal doses 
of cocaine (toxicity) but it can also effectively suppress many models of cocaine 
self-administration [15, 17, 19, 20].  Here we extend our investigation on the 
effectiveness of PEGylation, a technique effectively used to prolong the in vivo 
half-lives of many biologics and drugs [21], to prolong the in vivo half-life of 
CocE.  Short and long-chain PEG polymers, as well as large, branched versions 
48	  
covalently incorporated onto proteins serve as a stealthy means to evade the 
immune surveillance system, as well as in some cases stabilizing the protein 
itself [22, 23]. The latter characteristic is likely the result of protection against 
protease accessibility that would normally lead to degradation.  Likewise, we 
have previously reported on the capacity of PEGylation to prolong CocEs in vivo 
activity up to 48 hrs, representing more than a two-fold improvement over the 
non-PEGylated form [15].  
While these studies were valuable we sought to increase the stealth-like 
effects of PEGylation of CocE using a more systematic approach.  By first 
assessing which native cysteine residue(s) incorporate maleimide-conjugated 
PEGs we proceeded to utilize available structural information to engineer mutant 
forms of CocE to increase the PEG:CocE stoichiometry and thereby enhance the 
surface area of protection by PEG polymers.  More complete coverage should 
provide better stealth properties for the enzyme and result in longer in vivo 
lifetime.   
 
Site of PEG attachment and activity of PEG:CCRQ-CocE:  We have 
previously described the use of maleimide-coupled PEGs to PEGylate CocE. We 
prefer maleimide labeling over amine-coupling since there are only 4 cysteine 
residues (Cys107, Cys429, Cys477 and Cys551) in total per CocE protomer, as 
opposed to amine-coupling to a possible nine lysine residues.  Moreover, CocE, 
exists stably as a dimer, and has yet to be isolated as a monomer.  As we and 
others have demonstrated disulfide-mediated cross-linking and stabilization of 
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the dimer has been shown to significantly thermally stabilize the enzyme 
suggesting that the monomeric form is unstable [15], [24].  We therefore prefer 
not to risk interfering with the dimer interface with the placement of PEG 
polymers.  
In order to elucidate where PEG is attaching to CocE, we first generated a 
CocE mutant where all four cysteine residues were mutated to serine (CCRQ-
CocE-D4C) and then sequentially restored the cysteines one residue at a time 
using the CCRQ-CocE backbone.  While all mutants express, purify and display 
wild-type catalytic activity, only the mutant containing Cys551 efficiently 
accommodates a 40kDa branched PEG, as indicated by the large shift in the 
migration time through the SDS-PAGE gel (Figure 1). The gel shift was larger 
than expected for the addition of a 40 kDa PEG polymer however its aberrant 
retention time likely exacerbated by the charge to mass ratio of PEG and its poor 
capacity to bind SDS. Mutants C107S, C429S, and C477S do not appear to couple 
to PEG similar to CCRQ-CocE-D4C. Through the process of elimination we 
determined that only Cys551 is PEGylated in CCRQ-CocE, and likely in all of our 
previous PEGylation studies.  
The CCRQ-CocE (551) was PEGylated and resolved by anion exchange 
chromatography (Q sepharose) into 2 major and 2 minor peaks (see 
Supplemental data Figure S1, upper panel).  SDS-PAGE analysis of the peaks 
under non-reducing conditions reveals that the two major peaks (peak 2 and 3 in 
Figure S1) displayed considerable gel shifts compared to the unPEGylated peak 
4.  We surmise that the peak 3 contains only one PEG polymer per CocE dimer 
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whereas peak 2 contains two (ie. 1 PEG per CocE monomer).  Fractions 
contained in peak 2 were used for all subsequent experiments.  Peak 1 displayed 
no enzymatic activity (data not shown) that we suspect is simply dead protein.   
The purified PEG:CCRQ-CocE (C551) was subjected to our standard 
cocaine hydrolysis assay using non-PEGylated CCRQ-CocE as a control.  The 
results are plotted in Figure 2 and indicate indistinguishable effects on 
PEGylation on the catalytic properties of CCRQ-CocE (Vmax  ~2012 +/- 57 moles 
of cocaine per minute and KM of ~13.8 +/-1.1 µM) and PEG-CCRQ-CocE (Vmax  
~1982 +/- 54 per minute and Km of ~13.0 +/-1.01 µM).  
Single-site PEGylation at position 551 offered protection from cocaine-
induced lethality for 48 hrs relative to unPEGylated versions, which provided less 
than 12 hours of protection against cocaine-induced lethality (see Figure 2.5), in 
good agreement with previous studies [15].   
 
Incorporation of additional PEGs - Strategic attachment of PEG to CocE:  
Once we established Cys551 as the primary cysteine that accommodated the 
maleimide-PEG in wt-CocE (or CCRQ-CocE), our intent was to incorporate 
additional cysteine residues to accept PEG polymers in order to further extend 
the in vivo duration of the enzyme’s activity.  Our residue selection was based on 
maximizing the possible solvent accessible surface area of CocE that PEG 
moieties could ‘protect’ but still allow accessibility of the PEG polymers to the 
substrate cysteine residue.  Figure 2.3A depicts the x-ray crystal structure of the 
CocE dimer highlighting the enzymes three distinct domains: Domain 1 (yellow, 
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aa 1-144, aa 241-354), Domain 2 (blue, aa 145-240), and Domain 3 (green, aa 
354-574).  The figure also highlights regions on the surface of the enzyme that 
are likely protected by PEGylation of Cys551 alone, indicated by the transparent 
sphere (in panel A).  We selected nine candidate surface residues on the CocE 
dimer that are within the large surface area that are not likely protected by 
PEGylation of Cys551.  The candidate residues, modelled in red spheres in panels 
B (side view) and C (top view) were individually mutated to cysteines, expressed 
and purified and tested for enzymatic activity (summarized in Table 2.1). Those 
mutant enzymes that expressed well and exhibited full esterase activity were 
then PEGylated and subjected to in vitro (enzyme activity assays) and in vivo 
survival assay in mice using the cocaine-induced lethality model.  
 As indicated in Table 1 the best performing mutants with 2 PEG molecules 
attached per monomer were A92C and A330C.  The loss of protection against 
cocaine-induced lethality suggests that the second PEGylation site at residue 
330 provided no additional protection over the single PEGylation (Figures 2.4 
and 2.5A).  In contrast, incorporating an additional PEG moiety at residue 92 
provided greater than 72 hours of protection against cocaine-induced lethality, an 
additional 24 hours of protection upon addition of another PEG moiety.  
Since PEGylated CCRQ-CocE A92C performed best in the survival assay, 
this construct was used as the template for generating CocE mutants containing 
one additional PEG molecule per monomer (three total).  Here we attempt to 
utilize the crystal structure to guide the placement of a third PEG moiety, a 
process largely based on regional instability (ie. high anisotropy or high B- or 
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temperature-factor) and on their solvent accessibility.  Figure 2.4 illustrates the 
structure of the CocE dimer rendered to highlight the regional instability.  This 
rendering illustrates the anisotropic regions as a function of B-factor and is 
indicated by the thickness of the polypeptide chain and also by the color-coding, 
or heat map (red has the highest B-factor whereas blue has the lowest). 
Candidate residues were selected on regions of the enzyme that displayed high 
B-factors, with the assumption that unstructured regions might be more sensitive 
to proteolysis in the peripheral circulatory system.  In addition, these regions may 
likely incorporate a PEG moiety more efficiently without perturbing the structure 
and hence enzyme activity.  Indeed, incorporation of a third PEG moiety on most 
of the candidate residues did not appear to affect enzyme activity (Table 2.2).  
Unfortunately, with the exception of CCRQ-CocE A92C/S179C, all other triple 
mutants appeared to provide less protection against cocaine-induced lethality 
than CCRQ-CocE A92C (Figure2.5B). Moreover, the addition of a third PEG 
moiety per monomer of CocE (CCRQ-CocE A92C/S179C) did not appear to 
provide substantial additional protection over the PEGylated CCRQ-CocE A92C 
form of the enzyme (Figures 2.5B and 2.7).  
 
Analysis of PEG polymer length:  We previously demonstrated that branched 
40 kDa PEG polymer covalently labelled RQ-CocE [16] and CCRQ-CocE [15] 
prolonged in vivo half-life.  In this current study we compared the 40 kDa 
branched PEG polymer with linear 5, 10, and 20 kDa PEG molecules (Figure 2.6) 
using CCRQ-CocE A92C/S179C as a substrate.  Longer PEG polymers appear to 
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provide better protection with the branched 40 kDa PEG polymer providing the 
most effective protection against cocaine-induced lethality.  While 10 and 20 kDa 
PEGs could maintain in vivo enzyme activity and provide protection against 
cocaine-induced lethality for 24 and 48 hrs, respectively, the branched 40 kDa 
PEG polymer could protect for greater than 72 hrs.  Unfortunately we were 
unable to test branched PEG at less than 40 kDa nor linear 40 kDa PEG as they 




Since we were not able to provide dramatic enhancements in in vivo 
protection through adding more than 2-3 PEG per monomer versions of CocE, 
we speculate that we have achieved the maximum protection from this approach.  
Similar observations were recently reported in another thermostable form of 
CocE [24].  Analysis of the structure of the CocE dimer suggests that attachment 
of three PEGs to each monomer will cover most of the surface of the dimer 
(Figure 2.7 B). Specifically, one PEG molecule was placed on each of the three 
domains of CocE: A92C in Domain I, S179C in Domain II, and Cys551 in Domain III.  
The three residues are located on only one face of each monomer however since 
the dimer is arranged with 2-fold symmetry, the enzyme is protected. 
The observation that position S179C offered the stronger protection in our 3 
PEG per monomer group is intriguing.  Our earlier studies on developing a 
thermostable form of CocE, [25], found that Domain 2 of this protein (residues 
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145-240) has the highest flexibility that could lead to thermal instability.  Thus, 
generating L169K or T172R coupled with G173Q gave rise to the most thermostable 
mutant at that time.  It would follow that adding a large, flexible molecule such as 
a PEG polymer to this domain might perturb the structure enough to inactivate 
that protein through reversing the stability gained with the double mutation (RQ).  
Such was not the case as the S179C in the RQ background was fully active 
protein and offered the best in vivo protection, suggesting that the large but 
flexible PEG moiety did not perturb the structure of this helix-loop-helix. 
Figure 2.7 also illustrates that one region of the CocE dimer, located on the 
‘back-side’ of the Domain 3 is relatively unprotected. Analysis of mutants 
illustrated in Figure 2.4B suggests that placing PEG moieties on positions 384 
and 436 should provide a more extensive coverage of the dimer.  Unfortunately, 
the G384C mutant displayed poor enzymatic activity and was not tested for 
PEGylation or any subsequent in vivo experimentation.  Similarly, the T436C 
mutant, despite displaying wild-type enzymatic activity prior to PEGylation, 
appears less effective at protecting against cocaine-induced lethality even at 
early time points, suggesting that PEGylation of residue 436 was deleterious. 
The application of cocaine esterase as a therapeutic to accelerate the 
metabolism of systemic cocaine has shown significant clinical potential.  Indeed, 
the use of thermal stable mutants of this enzyme has progressed past Phase II 
clinical trials as a therapeutic, or rather antidote, against cocaine-induced toxicity.  
The protein half-live in vivo and in vitro is approximately 4-5 hrs [8], certainly long 
enough to allow for acute administration to lower systemic cocaine levels well 
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below toxic levels.  While we are thrilled that this enzyme is showing strong 
clinical potential to save cocaine overdose victims, our long-term goal with this 
project is to develop a protein-based therapy that can be applied to cocaine 
addiction, a procedure that would require good patient compliance or the use of 
therapeutics with long in vivo half-lives [14].  We have previously demonstrated 
that CocE administration in rats trained on cocaine can curb their craving for the 
drug in a dose dependent manner [19, 20].  These studies also suggest that 
CocE will be a more realistic therapeutic if it has a longer in vivo activity.  In this 
current study we utilized a structure-based strategy to engineer a form CocE that 
efficiently accommodates the stealth-like properties of PEG polymers, in order to 
evade systems of immune surveillance and proteolysis and to extend the in vivo 
half-life.  Our ability to provide more than 72 hours of protection against cocaine-
induced lethality following a single administration of our best version of 
PEG:CocE, suggests that PEGylated CocE may be display strong potential to 
abrogate cocaine self-administration and thus a viable treatment for cocaine 





Mutant Expression Activity 
A92C good +++ 
S99C poor - 
E103C poor - 
G324C good + 
T326C poor - 
A330C good +++ 
D355C good - 
A357C good * 
 
 
Table 2.1:  CocE residues selected for Cysteine replacement (2PEG per 
monomer)  Residues mutated to Cysteine for positioning additional PEGs 
around the CocE protein.  CCRQ CocE was used as the backbone for the 2 PEG 
per monomer mutants. Expression and activity levels are denoted next to each 
mutant.  Only fully active, good expressing mutants were examined in vivo.   
 
+++ = Full activity 
+ = Low activity 
- = No activity 





Mutant Expression Activity 
S179C good +++ 
D180C good +++ 
A181C good +++ 
Q191C poor - 
G201C good +++ 
L353C poor - 
G384C good + 
T436C good +++ 
G517C poor - 
 
Table 2.2. CocE residues selected for Cysteine replacement (3 PEG per 
monomer)  Residues mutated to Cysteine for positioning additional PEGs 
around the CocE protein using A92C (CCRQ-CocE) as a template to yield 3 
PEGs per monomer.  Expression and activity levels are denoted next to mutant.  
Only fully active, good expressing mutants were examined in vivo.   
 
+++ = Full activity 
+ = Low activity 
 - = No activity 















Figure 2.1:  PEGylation of CocE at Cys551.  CocE was systematically mutated, 
replacing three of four endogenous cysteine residues with serine, to interrogate 
which residue(s) incorporates a PEG polymer.  As a control, all four cysteine 
residues were mutated to serine to confirm that the PEGylation is cysteine-
mediated (lane Δ4C).  Incubation with a 40kDa branched maleimide-coupled 
PEG, only CocE with a cysteine at position 551 shows a gel shift in size due to 
the presence of covalently attached PEG.  Note that the free PEG is aberrantly 
migrating at approximately 70kDa and thus affecting the migration of the 















Figure 2.2:  CocE retains activity after PEGylation.  An in vitro 
characterization of the enzymatic activity assay was performed comparing 
CCRQ-CocE to the PEGylated enzyme (PEG:CCRQ-CocE).  Illustrated are the 
velocities of CCRQ-CocE converting cocaine into inactive metabolites ecgonine 
methyl ester and benzoic acid.  Kinetic constants of the PEGylated enzyme (Vmax  
~1982 +/- 54 moles of cocaine per minute and Km of ~13.0 +/-1.01 µM) are 
indistinguishable from unPEGylated CCRQ-CocE (Vmax  ~2012+/- 57 moles of 











Figure 2.3:  Position of endogenous and mutated cysteine residues on 
CocE.  The three domains of CocE are shown in yellow (I), blue (II) and green 
(III). A) Ribbon structure of the stabilized CCRQ-CocE dimer identifying Cys551 
from each protomer as the preferred PEGylated residues.  Highlighted is the 
hypothetical surface area protected by the 40 kDa branched PEG polymer if 
attached to Cys551. B) and C) Illustrated is the surface representation of the 
CCRQ-CocE stabilized dimer identifying candidate residues (A92, E103, G324, T326, 
T330, D355, A357 and C551) for our first round of PEG addition selected for their 
solvent facing R-groups and surface area coverage.  The candidate residues, 
rendered as red spheres, were individually replaced by cysteine and subjected to 
PEGylation. (B, side view; C, top view). The coordinates for CocE stabilized 
dimer (PDB: 3PUH, [15]) was rendered using Pymol (The PyMOL Molecular 









Figure 2.4: Enhancing the surface area protection by PEGylation.  Using the 
CCRQ-CocE-A92C/C551 as a template we identified additional residues on CocE 
that may offer further in vivo protection by PEGylation.  A) illustrated is the 
structure of CCRQ-CocE rendered as ‘putty’ to indicate regions of higher 
disorder, based on their temperature factors, or B factors. Also indicated are 
candidate residues rendered as pink spheres individually subjected to 
mutagenesis to cysteines as substrates for PEGylation. B) Candidate residues 
for this second round of mutagenesis that provides a third PEGylation site on 
CocE (S179C, D180C, A181C, Q191C, G201C, L353C, G384C, T436C and G517C and 
rendered as red spheres) are mapped on the surface representation of the 
















Figure 2.5:  In vivo protection against cocaine-induced lethality by 
PEGylated CocE. Purified preparations of CCRQ-CocE selected for PEGylation 
(ie, for 1, 2 and 3 PEG per monomer of CocE) and tested for their capacity to 
protect against cocaine-induced lethality, using the rodent model. A) Illustrated 
are the survival curves of PEGylated versions of CCRQ-CocE(C551) (1 PEG per 
monomer, gray dotted line), CCRQ-CocE-A92C(C551) (2 PEG per monomer, black 
circles and broken line) and CCRQ-CocE-A330C(C551) (2 PEG per monomer, 
open circles) representing the first round of mutagenesis (ie, 1 and 2 PEGs per 
monomer of CocE).  B) The effect of incorporating a third PEG per monomer of 
CCRQ-CocE on survival following cocaine administration (using CCRQ-CocE-
A92C(C551) as a template). Illustrated are the protective effects of CocE following 
the additional S179C (open circles), D180C (closed circles), A181C (open squares), 
G201C (closed squares), and T436C (open triangles) put in the CCRQ-CocE-
A92C(C551) background.  Preparations of the mutant enzymes were administered 
to mice at 32 mg/kg dose (i.v., tail vein) 30 minutes prior to challenge with 
cocaine (180 mg/kg i.p. cocaine injection). Animals were subsequently re-
challenged with cocaine every 24 hours following the initial administration of the 
CocE enzyme. All studies were done with 5 mice in each cohort (n = 5).  All 
experimental protocols were approved by The University Committee on the Use 


















Figure 2.6:  In vivo protection against cocaine-induced lethality by 
PEGylated CocE: effect of PEG complexity.  CCRQ-CocE-A92C/S179C(C551) 
was modified by PEG moieties of varying complexity and size polymers (5KDa, 
circles; 10KDa, squares; 20 KDa, triangles; and branched 40KDa PEG, inverted 
triangles). PEGylated enzymes were administered to mice at 32 mg/kg dose (i.v., 
tail vein) 30 minutes prior to challenge with cocaine (180 mg/kg i.p. cocaine 
injection). Animals were subsequently re-challenged with cocaine every 24 hours 
following the initial administration of the CocE enzyme. All studies were done 
with 5 mice in each cohort (n = 5).  All experimental protocols were approved by 
The University Committee on the Use and Care of Animals (UCUCA) at the 















Figure 2.7:  Enhancing the in vivo life-time of Cocaine Esterase through 
extending the protective coverage of the enzymes surface area offered by 
PEGylation.  A) Summary of the in vivo effects of incorporating 1 (C551, solid 
circles), 2 (A92C/C551, open squares), or 3 (A92C/S179C/C551, closed squares) PEG 
moieties per monomer of CocE as a protection against cocaine-induced lethality, 
compared to unPEGylated CCRQ-CocE (open circles).  B) Hypothetical 
protective coverage of the surface area of the CocE dimer through strategically 
placed PEG moieties provided by modification of residue 92 (transparent red 
sphere), 179 (transparent purple sphere) and 551 (transparent blue sphere).  
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Crystallographic Study of a Cocaine Analog bound to Cocaine Esterase 
and Inhibition of Cocaine Esterase 
 
Introduction 
 We have been developing cocaine esterase (CocE) as a protein-based 
therapeutic to treat cocaine toxicity and addiction.  One of the early mutant forms 
of CocE is currently being evaluated in Phase III clinical trials after having 
successfully completed the Phase II trial[1]. The results from this trial 
demonstrated the efficacy with which CocE can metabolize cocaine from 
circulation in humans.  Our group, in collaboration with Dr. Leonard Howell 
(Emory University) recently conducted a positron emission tomography (PET) 
imaging study cocaine clearance in living rhesus monkey[2]. The imaging studies 
looking at brain found clearance rates of cocaine similar to the human studies 
whereby almost no detectable cocaine was found fifteen minutes after cocaine 
administration when challenged with a PEGylated form of CocE. The ability of 
CocE to rapidly remove cocaine from peripheral circulation as well as the central 
nervous system (CNS) has promoted this protein to the forefront of potential 
drugs to treat cocaine toxicity.  We have also previously shown the potential for 
cocaine to recondition rodents away from cocaine seeking behavior[4].  Though 
CocE has exhibited the capacity for treating both immediate cocaine toxicity and 
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models of long-term addiction, using it as a prophylactic to treat cocaine 
addiction in humans will require an improvement in the catalytic properties to 
enhance its efficacy by also aid in drug formulation efforts.   
  CocE’s efficiency can be demonstrated through a ratio of its rate of 
catalysis (kcat) to the binding of substrate (Michaelis constant - KM) and is coupled 
to the rate of product release.  Improving the efficiency of an enzyme results from 
increasing the maximal velocity (Vmax) and/or decreasing the KM[5].  An increase 
in Vmax reflects an improved chemistry of hydrolysis in the active site.  Increasing 
the proton transfer rate between active site residues or increasing the rate of the 
nucleophilic attack on the substrate could potentially contribute toward improving 
the chemistry. Due to the catalysis of a substrate into a product in an enzyme, 
the binding rate of substrate to the enzyme is not the only parameter measured.  
Both the substrate binding (on rate –or- Kon) and release (off rate –or- Koff) reflect 
the substrate binding affinity and is related as the Michaelis constant (KM), the 
concentration of substrate at which the enzyme has reached fifty percent of its 
maximal velocity. Therefore, a decreased KM arises from better substrate binding 
[6]. 
 The first crystallographic study of CocE contained a non-covalently bound 
benzoic acid molecule modeled in the active site (PDB: 1JU4) [7].  The 
researchers were able to identify critical residues that were responsible for 
interacting with the partial product based on their coordination and proximity to 
benzoic acid.  Interestingly, in this study the authors report in that the benzoate 
appeared as a contaminant in their enzyme preparation and was not added 
69	  
exogenously during enzyme purification nor during crystallogenesis.  Note that 
the purification steps reported in the Larsen et al study were not rigorous and 
only entailed serial affinity chromatography steps.  Several aromatic residues 
surrounding the phenyl ring of benzoic acid, likely accounting for its high affinity, 
achieved the coordination, largely through Van der Waals interactions.  These 
data suggest that the strong coordination of this enzymatic product, benzoic acid, 
contributes to its slow off-rate and therefore to its role as the rate-limiting step in 
catalysis.  In order to improve CocE’s efficiency, we reasoned that a structural 
analysis of CocE’s active site could yield information by revealing residues that 
interact with cocaine and thus contribute to the Kon portion of CocE’s KM value. 
We wanted to build on this information gained from the partial product containing 
structure by generating a new structure of CocE with the intact cocaine substrate 
bound in the active site.   
 Trapping a molecule of substrate bound to an enzyme in crystallographic 
studies is extremely difficult without the use of catalytically impaired forms of the 
protein. Alternatively, non-cleavable substrate analogs (inhibitors) could be co-
crystallized, or soaked in the crystals, to approximate the nature of the substrate 
binding site.    In order to obtain such a model of substrate bound to the enzyme, 
we decided on two approaches:  1) use a catalytically inactive mutant enzyme 
co-crystallized with cocaine; or,  2) use a non-hydrolysable analog of cocaine 
trapped in a complex with the enzyme.  Of the three residues in CocE that form 
the catalytic triad (Ser117, Asp259 and His287) we first targeted the Asp259 and 
replaced it with an Asn residue. While we were able to isolate, crystallize and 
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even determine structures of the soaks, no success was gained in obtaining 
structures bound to non-hydrolyzed cocaine.  As it turns out we were, however, 
able to obtain a structure of an acyl-enzyme intermediate of the enzyme.  While 
this extremely interesting structure is informative regarding catalysis and is the 
subject of the following chapter, it does not reveal anything regarding the 
contributions of the tropane ring of cocaine to binding affinity and thus the KM. 
We thus sought to test whether non-hydrolyzable substrate analogs of cocaine 
(i.e. – non-ester containing molecules) that could be trapped in the binding site.  
Using this latter approach we were fortunate to obtain a data set and delineate a 
high-resolution structure of CocE bound to a tropane-containing cocaine 
analogue.  As these two approaches yielded significantly different results that 
may be applied to either understanding catalysis, kcat (acyl-enzyme intermediate) 
or understanding substrate binding, KM (non-hydrolyzable cocaine analog-bound 
CocE), each approach has been divided into separate chapters.  
 Studying an enzyme’s mechanism of action on its endogenous substrate 
has proven difficult due to their inherent activity.  One approach to elevating this 
problem comes from using a substrate analog that is structurally similar to the 
endogenous substrate but lacks the ability to be converted to a product by the 
enzyme[8, 9].  Structural studies with kinases give multiple examples of this 
approach.  Due to the transfer of the γ-phosphate from ATP to the awaiting 
serine, threonine, or tyrosine residue, studying the positioning of both ATP and 
protein target in the kinase active site becomes problematic.  Using a non-
hydrolyzeable ATP analog, AMP-PNP - that contains an imido linkage between 
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the β- and γ-phosphates, protein crystals can be generated with both ATP and a 
target protein bound to the kinase[9, 10].  Information gathered from these 
studies aid in determining the residues that come in contact with either substrate 
prior to enzymatic turnover or product after turnover.   
 In order to investigate the physiological effect of cocaine, several cocaine 
analogs have been developed that are capable of blocking reuptake at 
monoamine transporters, with each analog having a unique and distinct structural 
makeup compared to cocaine [11-13].  Since several of these analogs do not 
contain a internal ester bond between the phenyl and tropane ring portions, we 
reasoned that these molecules could be used in our crystallographic studies in 
lieu of the actual substrate, cocaine. 
 We were able to procure two non-hydrolyzable cocaine analogs:  RTI-150 
and WIN 35,065-2 (see Figure 3.1).  The RTI-150 compound was originally 
synthesized to study the capacity of phenyltropane molecules to binding to 
dopamine transporters.  This molecule showed five times the potency at DAT 
versus cocaine [11, 14] while WIN 35,065-2 displayed several times higher 
potency than cocaine at DAT, but a lower affinity at SERT compared to cocaine 
[12, 15].   
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 Our crystallographic analysis of the cocaine analog-CocE complexes 
yielded results with electron densities corresponding to either RTI-150 and WIN 
35,065-2 in an overlapping position; however, the ligand density was distinctly 
removed from the enzyme’s active site, based on the benzoic acid structure, as 
well as our new acyl-enzyme intermediate structure, Because this site does not 
overlap with our projected substrate-binding site, we reasoned that if these 
analogs could be acceptable cocaine surrogate molecules, they might be able to 
inhibit the enzyme in some fashion.  In other words, if they bind to the active site, 
they could function as a competitive inhibitor.  Alternatively, if they bind at 
another site, yet still influence enzyme kinetics, then they could be an inhibitor of 
some other classification.   
Testing these two compounds for their potential to inhibit CocE 
immediately presented a problem due to our convention for testing activity of the 
enzyme.  We have relied on an absorbance-based assay that measures the 
decrease of cocaine absorption.  Since both of the inhibitors used in this study 
Figure 3.1:  Structures of non-hydrolyzable cocaine analogs RTI-150 and 
WIN 35,065-2.  RTI-150 and WIN 35,065-2 shown above structure of cocaine.  
Both molecules lack the ester bond connecting the phenyl and tropane rings, 





absorb at 240 nm as well, we were unable to use the same assay for determining 
inhibition of CocE with RTI-150 or WIN 35,065-2.   
In an attempt to find a more suitable substrate for testing the activity of 
cocaine esterase, we found a compound that could be used in fluorescence and 
absorbance based assays that contained an ester bond.  Resorufin acetate (RA) 
is a tricyclic compound that shows a shift in fluorescence and absorbance after 
cleavage of its ester bond.  We have been able to utilize this compound in our 
CocE activity assays in order to analyze the inhibition of benzoic acid (product of 
cocaine hydrolysis), and the inhibitors RTI-150 and WIN 35,065-2.  With the 
development of a new activity assay for CocE, using resorufin acetate as a 
substrate, the inhibition of CocE with either inhibitor can be monitored without the 





Figure 3.2:  Structure of Resorufin Acetate 
Resorufin Acetate, 7-acetoxy-3H-phenoxazin-2-one, is a tricyclic 
molecule with a methylester group that induces a shift in absorbance 
and fluorescence emission when hydrolyzed[3]. PubChem CID: 




Generation of CocE:  The mutants of CocE were generated using a variation on 
the Quick-Change method for site directed mutagenesis mentioned previously 
[16].  Oligonucleotides directed towards A51E: 5' -GAC GTG TTC GAA TGG TCG 
ACG - 3'; A51N: 5' - GAC GTG TTC AAC TGG TCG ACG - 3'; Q55E: 5' - TGG 
TCG ACG GAA TCG ACA AAC - 3'; L169E: 5' - TGG TCA GCT GAA ATA GGT 
CGC - 3'; I170K:  5' - TCA GCT CTC AAA GGT CGC CAG - 3'; I170Q: 5' - TCA 
GCT CTC CAG GGT CGC CAG - 3'; I170R: 5' - TCA GCT CTC CGT GGT CGC 
CAG - 3' were ordered from Integrated DNA Technology (La Jolla, CA) The 
thermostable mutant of cocaine esterase with the longest acting in vivo activity 
was used in the RA analysis (92-CocE). The gene encoding CocE was 
expressed from pET-22b (+) plasmid in BL21 (DE3) (Novagen) bacterial cells.  
Cells were grown to OD600 = 0.6 AU, temperature shifted to 18°C, and protein 
expression was initiated with the addition of 1mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Genesee Scientific).  Expression continued for 16 
hours, and cells were pelleted and stored at -80°C until purification.  The cell 
pellet was resuspended in 1X Tris-buffered saline (TBS) and broken with two 
passes through a French Press.  (ThermoScientific)  Bacterial lysate was clarified 
by centrifugation at 25,000 x g and loaded onto a Ni2+NTA column equilibrated 
with 1 x TBS at pH 7.4.  The protein was eluted using 1 x TBS with 150 mM 
imidazole.  Protein dimers were covalently cross-linked by incubating with 50 µM 
CuCl2 at 4°C overnight.  The entire reaction was loaded onto a Q-sepharose 
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column equilibrated with 50 mM Tris, pH 8.0.  CocE protein was eluted off with a 
gradient of NaCl in buffer B.  Peak fractions were analyzed with 10 % SDS-
PAGE, then pooled and concentrated to 10 mg/ml with Amicon concentrators 
(Millipore) and stored at -80°C.   
Generation of Crystal Structures:  CocE crystals were grown by hanging drop 
vapor diffusion in 24-well VDX trays (Hampton Research).  One microliter of 
protein (either inactive D259N or H287A, or RQ-CocE with WIN and RTI 
compounds) and well solution (18% PEG (average size = 3550 kDa), 25 mM 
MES pH 6.5, 1 M NaCl) were mixed on siliconized glass coverslips (Hampton 
Research) and placed over 1 ml of well solution.  Trays were incubated at 12°C 
and crystal growth was observed after 2-3 days.  Crystals were scooped and 
placed in cryoprotectant (well solution supplemented with 20 % glycerol) alone or 
with saturating solution of either WIN 35,065-2 or RTI-150 and allowed to 
incubate at room temperature for 5 minutes.  Crystals were mounted on proper 
sized loops (0.2 – 0.4 µm – Hampton Research) and flash frozen in liquid 
nitrogen.  X-ray diffraction data were collected at the Advanced Photon Source 
(Beamline 21-ID-D).  Data were integrated and scaled using HKL2000[17].  
Molecular replacement by Phaser was run using 3IDA structure of KQ-CocE as 
the search model.  Successive rounds of refinement were performed using 
Phenix software [18] and manual density fitting using Coot [19].   
Cocaine esterase activity assays:   Cocaine assay:  Purified PEG:CocE was 
analyzed using our standard absorbance-based cocaine assay, described 
previously. (Brim, 2011)  Here, cocaine (Mallinckridt, Hazelwood, MO) is added a 
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96-well UV-permeable plate (Costar; Corning Life Sciences, Lowell, MA) at 200, 
100, 50, 25, 10, 5, 1 and 0.5 µM concentrations. The reaction is initiated by the 
addition of PEG:CocE (65 ng/ml) at a 1:1 dilution in the plate. The velocity of the 
reaction was measured every 10s for 20 minutes by a SpectraMax Plus 384 UV 
plate reader (Molecular Devices, Sunnyvale, CA) using SOFTmax Pro software 
(version 3.1.2).  The absorbance readings were converted to change in 
concentration of product using using Beer’s law.  The specific activity of the 
enzyme was plotted using Prism software (GraphPad Software Inc., San Diego, 
CA) and kinetics of the reaction (kcat and Km) generated. 
Resorufin Acetate Assay:  Assays with resorufin acetate were conducted in the 
same manner as the cocaine based assays with the exception of a difference in 
concentration of substrate.  RA was diluted to 400, 200, 100, 50, 25, 10, 5, 2.5 
µM in PBS.  The assays were performed at 37°C for 1 hour, while the increase of 
absorbance at 570 nm is recorded at 2-minute intervals. 
Inhibition assays with WIN and RTI:  WIN 35,065-2 and RTI-150 were 
dissolved in dH20 to a final concentration of 10 mM.  The resorufin acetate assay 
was used to measure the inhibition potential of both compounds.  The assays 
were performed by adding inhibitor to the reaction at several concentrations: 
1000, 333, 33, and 10 µM.   
Dixon and Cornish-Bowden analyses:  Data from the kinetic analysis of the 
inhibition studies were plotted as either the reciprocal of the velocity (1/v - Dixon 
plot) or the concentration of substrate over velocity (s/v – Cornish-Bowden plot) 
using Prism software (Graph Pad Software Inc., San Diego, CA).   
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Drugs:  RTI-150 and WIN 35,065-2 were kindly provided by Dr. F. Ivy Carroll 




Structure of inhibitors:  Both inhibitors have a nitrogen-containing tropane ring 
and a phenyl group as part of their molecular makeup.  RTI-150 (C20H27NO2) ((-)-
2β-carbocyclobutoxy-3β-(4-methylphenyl)tropane) (PubChem CID – 9972881) 
also has a cyclobutane group off of its sole ester bond.  In this molecule, the 
phenyl ring contains a methyl group at the para position of the tropane ring.  WIN 
35,065-2, (C16H21NO2) ((-)-2β-Carbomethoxy-3β-pheyltropane) (also known as 
troparil – PubChem CID – 170832) has a methylester and a phenol group coming 
off of the tropane ring at positions 2 and 3, respectively.   
 
Crystallographic analysis of CocE bound to RTI-150 or WIN 35,065-2:  Using 
hanging drop vapor diffusion of CocE crystallization media containing RTI-150 
we were successful in obtaining crystals large enough to diffract greater than 
1.8Å (Figure 3.3).  Although similar co-crystallization attempts were unsuccessful 
with WIN 35,065-2, crystal soaks with saturating concentrations of the cocaine 
analog did yield diffracting crystals.  
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Data sets for both structures were generated at a resolution limit of 1.8 Å. 




Figure 3.3:  Crystals and x-ray diffraction of RTI-150-CocE Complex.  A) 
Crystals grown in 18% PEG3550, 25 mM MES pH 6.5, 1 M NaCl in 1 mM RTI-
150 at a protein concentration of 10 mg/ml under vapor diffusion at 12C.  B) 
Diffraction pattern of an RTI-150-CocE Complex crystal was collected at LS-
CAT at APS in Argonne National Laboratories. 
Figure 3.4A: Structure of RTI-150-bound CocE.  Highlighted is the 
electron density (blue mesh).  The active site, defined by the catalytic 
residues, Ser117, Asp259 and His287, are highlighted in magenta spheres.  
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CocE structures generated under similar conditions.  Table 3.1 contains all 
refinement statistics.   
Composite omit maps of the RTI-150-bound CocE density with respect to 
unliganded CocE reveals a strong density located between the Domain I and II 
but at a site 8Å away from the active site, based on the structure benzoic acid-
bound CocE (PDB: 1JU4) (Figure 3.4 A and B).   
The co-crystallization of RTI and soaking in of WIN yielded similar results.  
Electron densities that correspond to the shape of each molecule were found 
positioned between helices of Domain I and II, but distant from the active.  This 
position, however, does not correspond to where we believe cocaine sits in the 
Figure 3.4B:  Electron density in the RTI-150-CocE crystals Density found 
at a site distal from the putative active site based on the benzoic acid-bound 
CocE structure (PDB: 1JU4).  RTI-150 is (rendered in yellow) and benzoic acid 
(sage) are illustrated.  Note that the electron density indicates the presence of 
the cocaine analog binding site on CocE where its phenyl ring is at least 8Å 
away from the location of benzoic acid binding site. 
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active site, and also, this position would put the substrate too far from the active 
site residues for chemistry of hydrolysis to occur.   
The nitrogen of the tropane ring is closest to the exterior solvent exposed 
face of the protein, and the more hydrophobic methylbenzene and cyclobutane 
ring portions of RTI-150 point inward towards the active site pocket with more 
hydrophobic residues.  (Figure3.6) 
As illustrated in Figure 3.4 electron density compatible with models of both 
RTI-150 (Figure 3.5A) and WIN 35,065-2 (Figure 3.5B) and suggest a similar 
binding site for the cocaine analogs and likely for cocaine itself.  Though we 
collected datasets on CocE complexes that show density corresponding to the 
structures of either WIN 35,065-2 or RTI-150, the RTI density was much more 
complete, therefore the remainder of the analyses will be restricted to the RTI-
150-bound CocE complex structure (see Figure 3.6).   
A) B
)
Figure 3.5: Structure of the non-hydrolyzable cocaine analogues bound 
to CocE. Illustrated is cocE and the members of the catalytic triad (magenta 
spheres).  A) CocE bound to RTI-150 (fleshtone) and corresponding electron 
density (blue mesh).  Superimposed is the cocaine modeled onto the tropane 
ring.  B) CocE bound to WIN 35,065-2 (grey) and corresponding electron 
density (magenta mesh). Superimposed is the cocaine modeled on the 




The binding site for cocaine suggested by the structures of the cocaine 
analogues away for the site of hydrolysis is unanticipated.  One interpretation 
may be that the relatively hydrophobic cocaine analogs merely took advantage of 
a hydrophobic surface on CocE at a site that is catalytically unrelated to the 
active site for cocaine itself.  The notion is that cocaine, owing to its slightly 
different structure (ie. presence of an ester linkage) would bind preferably to the 
catalytic site implied by the benzoic acid-bound CocE structure.  Alternatively, 
this novel site may actually represent legitimate docking site through which 
cocaine passes through on its way to the catalytic site.  In this model the 
Figure 3.6:  Electron density of RTI-150-containing CocE structures.  The 
position of this novel site is distal from the active site (magenta spheres).  
Right panels display four different views of the RTI-150 model overlayed into 
the electron density (blue mesh). 
82	  
substrate cocaine may initially dock at this entrance to the CocE active site, prior 
to hydrolysis, where it may be desolvated in order to enter the enzyme’s active 
site.  To test whether this site is relevant to cocaine binding and hydrolysis and 
not merely a binding site that is specific to the non-hydrolyzable cocaine analogs, 
we generated a series of site-directed mutagenesis studies and assessed their 
capacity to influence the KM of cocaine.  
Looking at the potential molecular interactions between the RTI-150 
structure and residues in CocE, we identified several residues within van der 
Waals and hydrogen bonding distances from RTI-150 in our model.  The 
residues in closest proximity to the RTI-150 are Tyr44, Ala51, Gln55, Leu169, and 
Ile170 (see Figure 3.7).  
Tyr44 is one of two residues (also Tyr118) that form the oxyanion hole, and 
is shown to be crucial for enzyme functioning as mutagenesis to Phe yields a 
catalytically dead enzyme [7].  Both Ala51 and Gln55 extend off of the A1 helix of 
DOM1.  The methyl group off Ala51 resides approximately 5 Å away from the 
methyl attached to the nitrogen atom of the tropane ring of RTI-150.  The methyl 
group of Ala51 also resides ~3.8 Å away from the carbonyl carbon of cyclobutane 
ester of the tropane ring of RTI-150.  Like Ala51, the sidechain of Gln55 is 
positioned ~5 Å from the cyclobutane ring of RTI-150 in our model.  On the 
opposite face of the cocaine analog the sidechains of both Leu169 and Ile170 sit 
close enough to the methyl phenyl group of RTI-150 to form extensive van der 
Waals contacts (Figure 3.7).   
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Putative docking site residues 
Ala51 and Gln55:  The crystal structure of the RTI-150 CocE complex suggested 
that residues at positions 51 and 55 may influence binding of cocaine substrate 
to the active site.  Interestingly these residues were also identified in an 
computational study of CocE using molecular dynamic simulations suggesting a 
possible interaction with the tropane ring of cocaine[20].  They further predicted 
that mutating these residues to glutamate might enhance the interaction between 
the residue and substrate by forming additional attraction between the nitrogen 




Figure 3.7:  CocE residues 51 and 55 that may contribute to cocaine 
binding.  Left panel illustrates the native CocE residue Ala51 and Gln55 .  Right 




As summarized in Table 3.2, analysis of these residues by site-directed 
mutagenesis and substitution to glutamate significantly improves the KM of the 
enzyme with a mild decrease in the maximal velocity.  Substitution of either 
residue to glutamate improves the KM by approximately 5-fold over WT-CocE or 
CCRQ, the thermostable for of CocE.  The fact that the Ala51Glu displays such a 
dramatic effect on the KM of cocaine not only validates the model predicted by 
Huang et al [20], but also strongly supports that the putative cocaine docking site 
predicted from our RTI-150-CocE structure.  In this model the sidechain of 
Ala51Glu would interact directly with the bridging nitrogen of cocaine and enhance 
its binding.   
The dramatic observed improvement in the KM and most likely the 
improved affinity at the docking site may actually negatively affect the Kcat of the 
enzyme.  In this manner the maximal velocity of the Ala51Glu mutant may 
negatively affect the Vmax through slowing the transition from the docking site to 
the active site.  This rationale is supported by kinetic analysis of the Ala51Asn 
mutation.  The improved cocaine binding results from an interaction with the 
oxygen of the carboxamide of asparagine and the bridging nitrogen on the 
tropane ring.  Since there is not a fully formed hydrogen bond through the 
carboxylate side chain (i.e. of Glu) and the bridging nitrogen, the substrate’s 
Table 3.2:  Kinetic values of CocE mutants – A51E, A51N, and Q55E 
Mutants KM (µM) Vmax (min-1) 
Catalytic Efficiency  
(µM-1•min-1) 
Ala51Glu 5.5 +/- 0.8 920+/- 41 168 
Ala51Asn 15.3 +/- 3.0 2200 +/- 118 143 
Gln55Glu 4.1 +/- 0.7 750 +/- 30 184 
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transition may be less impeded to the active site and display a WT-like maximal 
velocity.   
 
Leu169:  Residue 169 lies in the middle of helix 2 of DOM2 and faces towards the 
active site cleft (See Figure 3.8).  We have previously identified a thermostable 
mutant of CocE, Leu169Lys that together with Gly173Gln displayed the highest 
reported velocity of any mutant of CocE, and it also remained active for almost 3 
days at 37°C in buffer [21].  Based on crystallographic evidence we reasoned 
that the ζ-nitrogen can hydrogen bond with the hydroxyl of Tyr44, and provide 
added structural stability to CocE.  Why this mutant was able to perform 
chemistry almost three times faster than other CocE mutants was unclear at the 
time.  In order to evaluate the potential of this basic residue substitution, we 
investigated placing an acidic residue with the hypothesis that it would have an 
opposite effect. 
 
Figure 3.8:  Leu169 may contribute to the docking site of cocaine. 
Illustrated is the native Leu169 (Left panel) and the Leu169Glu (right panel) with 
respect to the putative cocaine docking site. 
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The goal of this mutation was to disrupt the potential van der Waals 
contacts between the sidechain of Leu169 and the benzoyl moiety of cocaine (See 
Figure 3.8).  However, as illustrated in Table 3.3 there was not a dramatic effect 
on the overall kinetics of cocaine hydrolysis by Leu169Glu mutant of CocE and if 
anything there was a slight improvement in KM with no change in the enzymes 
Vmax.  This improvement to KM may be analogous to the effect of Ala51Glu on its 
interaction with the tropane ring but its modest effect may be due to the large 
hypothetical distance between the bridging nitrogen on the tropane ring of 
cocaine and oxylate group of Leu169Glu.  
 
Ile170:  Residue 170 lies in the middle of helix 2 of DOM2 and faces towards the 
active site cleft (see Figure 3.9).  The δ-carbon atom of this residue could 
potentially interact with the tropane ring or the methyl group off the nitrogen atom 
of the tropane ring.   
As indicated in Table 3.3 substitution of Ile170 to either Lys, Gln or Arg 
yields similar but high KM values that are outside of the detectable limit (ie. 
beyond our maximal concentration of substrate).  We intentionally chose 
residues with bulkier R-groups to mimic that of isoleucine, but selected charged 
residues hoping to influence the kinetics in one of two ways.  First, lysine and 
Table 3.3:  Kinetic values of CocE mutant – Leu169Glu 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency  (µM-
1•min-1) 
Leu169Glu 17 +/- 3.0 2600 +/- 160 157 
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arginine were selected in hopes that their positive charge might repel the tropane 
ring in the ecgonine methylester partial product in a way that would increase 




cocaine and increase the KM.  Second, glutamine was selected to complement 
the above strategy with basic residues but by having a substrate facing oxygen 
atom that could potentially attract the nitrogen atom in the tropane ring, via 
hydrogen bonding.  Improving the interaction prior to hydrolysis in a manner that 
may improve the KM.  Here the results indicated the dramatic loss KM to over 100 
Table 3.4:  Kinetic values of CocE mutants – Ile170Lys, Ile170Gln, and Ile170Arg 
Mutation KM (µM) Vmax (min-1) 
Catalytic Efficiency 
(µM-1•min-1) 
Ile170Lys >100 1900 +/- 190 NC 
Ile170Gln >100 1800 +/- 490 NC 
Ile170Arg >100 1700 +/- 150 NC 
Figure 3.9: The contributions of Ile170 to substrate binding to CocE. A) 
native CocE residue Ile170 with cocaine modelled in its putative docking site. 
The hypothetical positions of sidechains of mutants Ile170Lys (panel B), 
Ile170Gln (panel C) and Ile170Arg (panel D).  
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µM in all three mutants such that the overall catalytic efficiency was not 
calculated.  They data do suggest however that the maximal velocity of each 
mutant is unimpaired.   
Taken together these results strongly support the location of putative 
cocaine docking site model by demonstrating a loss of substrate’s capacity to 
bind to CocE upon mutagenesis of residues that coordinate RTI-150 binding.  By 
placing a large, charged or uncharged residue in place of the hydrophobic 
isoleucine, the KM increased several fold.  The fact that each mutant enzyme 
retained high activity suggests that the mutations do not interfere with the 
chemistry of cocaine hydrolysis by CocE and strongly support the notion that the 
site identified by the RTI-150-CocE crystal structure is a bona fide binding site for 
cocaine, perhaps serving as a docking site. 
 
Catalysis using the resorufin acetate fluorescence assay: The 
crystallographic data with the cocaine analogs suggests that they may bind 
preferentially to a site distinct from the active site; however, mutagenesis of 
residues surrounding this site appeared to dramatically affect cocaine hydrolysis.  
These data suggest that the analogs may inhibit cocaine esterase even through 
binding to this docking site.  To measure this inhibition, we developed a new 
absorbance-based assay using following resorufin acetate (RA) hydrolysis. 
Resorufin absorbs at 570 nm after hydrolysis of the ester-bonded acetate.  The 
ability to measure absorbance at 570 nm has significant advantages over our 
standard absorbance-based cocaine assay since both benzoic acid and the 
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analogues contain phenyl rings that absorbs in the UV spectra. Hydrolysis was 
measured as an increase of absorbance at 570 nm. 
 The assay was conducted using dilutions of RA listed in the materials and 
methods section.  The most thermal stable form of CocE (CCRQ-A92C) was 
used as the test protein in these assays.  Several assay times were tested 
ranging from 20 minutes (similar to the cocaine based assay) out to 6 hours.  We 
found that a one-hour assay was adequate to assay CocE’s hydrolysis of this 
substrate and within the linear progress curve.  The kinetics of RA hydrolysis 
were determined to be a KM of 67µM and a Vmax of 850 min-1.  (Figure 3.10) 
 
Inhibition of resorufin acetate hydrolysis by Benzoic acid: By taking 
advantage of the spectral properties of resorufin acetate during hydrolysis we 
tested the capacity benzene containing molecules (eg. RTI-150, benzoic acid) to 
inhibit its hydrolysis by CocE.  We surveyed four different concentrations of 
Figure 3.10:  Resorufin Acetate assay. CocE at concentration of 100 
ng/ml was found to hydrolyze resorufin with a KM~67 µM and a Vmax~ 
850 min-1.  
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benzoic acid were tested – 1000 µM, 500 µM, 333 µM, and 33 µM.  These 
concentrations were selected because they encompassed the entire range of RA 
substrate concentrations in the assay.  The Michaelis-Menton plot of benzoic 
acid inhibition of RA hydrolysis displays a concentration-dependent inhibition.  
The inhibition also decreased the Vmax of the reaction while simultaneously 
increasing the KM.  (Figure 3.11)   
 
 
 With these kinetic parameters, a reciprocal plot of the velocity was 
performed to generate a Dixon analysis [22] to determine the type of inhibition by 
benzoic acid (Figure 3.11 right panel).  Examining the point of intersection on the 
x-axis of each line representing substrate concentration, the benzoic acid has an 
apparent Ki value of ~355 µM.  (Figure 3.9)  The Dixon analysis also shows that 
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Figure 3.11:  Inhibition of CocE hydrolysis of RA by benzoic acid.  Left panel 
shows the Michaelis-Menton plot of concentration dependent decrease of Vmax and 
increase of Km by benzoic acid.  Right side displays the Dixon plot of the same 
inhibition assay.  By plotting the reciprocal of the velocity (1/v) of each 
concentration of RA, the plot shows benzoic acid to be a noncompetitive inhibitor.   
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benzoic acid fits the pattern of a noncompetitive inhibitor, consistent with a 
product-type of inhibition. 
 
Inhibition of resorufin acetate hydrolysis with RTI-150:  We next assessed 
the capacity of RTI-150 to inhibit resorufin acetate hydrolysis by CocE.  We 
tested four concentrations of RTI-150 (1000 µM, 500 µM, 333 µM, and 33 µM) to 
inhibit resorufin acetate hydrolysis by CocE.  The assay was set up in the same 
manner, using the same assay parameters with the same substrate/inhibitor 




After plotting the inhibition data, the results of the Dixon analysis were 
unclear (Figure 3.12 middle panel) but did indicate that the Ki of RTI ≈ 1340µM.    
The regression lines for each concentration of substrate all intersected below the 
x-axis, suggesting a mixed, competitive and non-concompetitive inhibitors, 
Figure 3.12: Inhibition of CocE hydrolysis of RA by RTI-150.  Top panel 
shows MM kinetics of RA assay with RTI-150’s concentration dependent 
inhibition.  Middle panel is the Dixon plot of same inhibition assay.  Due to the 
intersection of each plotted line being below the x-axis, method of inhibition is 
unclear.  Bottom panel shows the Cornish-Bowden analysis showing 
noncompetitive inhibition.    
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according to the closest interpretation of traditional Dixon analysis.  Cornish-
Bowden analysis (Figure 2.12, lower panel) of the same assay data, which 
normally can differentiate more stringently between competitive and mixed 
inhibitors also revealed a mixed mode of inhibition [23].  The statistics of the 
inhibition studies support the goodness of fit for our data, but as mentioned 
earlier, this substrate is not ideal due to the solubility issues.   
 
Discussion 
 The inhibition of CocE-mediated hydrolysis resorufin acetate by RTI-150 
has lent some support to the crystal structures solved in this study.  The results 
suggest that RTI-150 can inhibit hydrolysis in either a noncompetitive or a mixed 
type of inhibition, consistent with the notion that RTI-150 may bind to multiple 
sites (Figure 3.12).  It is tempting to speculate that RTI-150 may bind to the 
docking site of CocE, as indicated by the crystal structure, and non-competitively 
inhibit access to the catalytic site.  Alternatively, RTI-150 binding to the docking 
site may allosterically alter the enzymes capacity to hydrolyze the substrate 
through altering the enzymes kcat.  The mixed mode of inhibition indicated by the 
resorufin acetate hydrolysis data suggests that RTI-150 may also inhibit in a 
competitive manner directly at the active site.  
Regardless of the mode of inhibition, the resorufin acetate hydrolysis data 
do support the existence of an additional site for the cocaine analog and together 
with the mutagenesis data suggest that this site could also be occupied/utilized 
by cocaine. 
94	  
 We understand that the results need to be viewed through two potential 
limitations.  First, the solubility of RA in water was an initial challenge that took 
several approaches before finally settling on the current assay.  Looking at the 
kinetics, however, we believe that this assay is reflective of the actual kinetic 
values of RA when hydrolyzed by CocE. (Figure 3.10)  Secondly, the inhibition 
assay was performed with RTI-150 inhibiting RA hydrolysis and not measuring 
the inhibition of cocaine hydrolysis directly.  We do not know exactly where RA 
binds to CocE during hydrolysis, but we have shown that it is a substrate for this 
enzyme.  
The position of RTI-150 in our CocE structure was a surprising result.  The 
intent was to generate a surrogate model of cocaine binding to the active site by 
using a non-hydrolysable cocaine analog (either RTI-150 or WIN 35, 065-2) 
together with a fully active CocE mutant (RQ-CocE).  Since the structure solved 
generated from the WIN 35, 065-2-containing crystals show incomplete electron 
density, it was not fully refined nor was it used as a model to test residues that 
could potentially interact with cocaine.  The fact remains, however, that this 
molecule does bind to the same region of CocE as RTI -150 giving support to the 
existence of a cocaine docking site.  We then needed to elucidate whether or not 
this is a bona fide binding site for cocaine substrate.   
Based on the crystallographic results, we initially hypothesized that RTI-
150 bound to an initial binding site where cocaine is positioned prior to moving 
into the active site for hydrolysis (see Figure 3.13).  We further reasoned that this 
site might be used to desolvate the substrate prior to moving into the active site.  
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We have noticed that the CocE active site contains a rather sizeable hydrophobic 
presence, primarily composed of aromatic residues.  The salt form of cocaine is 
readily dissolved in water presumably due to the nitrogen on the tropane ring and 
two esters elsewhere on the molecule that act as 5 distinct sites of hydrogen 
bond acceptors[24]. In order to fit properly into the active site, prior to hydrolysis, 
the molecule may need to shed bound waters for proper positioning between the 
catalytic triad.  We reasoned that this process might be initiated by binding at the 
site where RTI-150 was located in the crystal structure.   
 
In order to test the legitimacy of this docking site to cocaine hydrolysis, we 
utilized site-directed mutagenesis to test whether residues proximal to RTI-150, 
Tyr44, Ala51, Gln55, Leu169, and Ile170 all sit in close enough to the tropane analog 
to potentially influence cocaine binding.  Tyr44 has been previously shown to be 
part of the two-component oxyanion hole, and mutation of this residue to 





Figure 3.13: Two putative substrate binding sites on CocE. Illustrated is a 
model of the substrate cocaine bound to the active site (magenta) based on 
the structure of CocE bound to benzoic acid (PDB: 1JU4) or the docking site 
(cyan) based on the RTI-150 crystal structure.    
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Since its presence is deemed crucial to enzyme activity, it will not be mutated in 
the future study.   
Ala51, Gln55, Leu169, and Ile170 were all found in close enough proximity to 
interact with the RTI molecule and will be explored for potential to influence 
enzymatic efficiency.  A previously reported study of cocaine binding to the active 
site of CocE (based on the benzoic acid-CocE complex structure) using 
molecular dynamic simulation suggested that both Ala51 and Gln55 could interact 
with the bridging nitrogen of the tropane ring of cocaine and influence its binding 
[26].  This proposed interaction was predicted to enhance the KM of cocaine 
despite the large distance of Ala51, in particular, to the bridging nitrogen of 
cocaine in the active site (see Figure 3.14).  The researchers postulated that a 
mutation to glutamate at either of these positions should improve the KM of 
cocaine binding and our biochemical data confirmed this. 
Figure 3.14: Potential interaction of Ala51Glu with the bridging nitrogen 
on cocaine in the docking vs active sites.  Illustrated is a model of the 
substrate cocaine bound to the active site (magenta) based on the structure of 
CocE bound to benzoic acid (PDB: 1JU4) or the docking site (cyan) based on 
the RTI-150 crystal structure and mapped on to the Ala51Glu mutant.  Rotomer 
selection the Ala51Glu sidechain was based on minimizing clashes with 
substrate.  Distances between the oxalate and bridging nitrogens of cocaine in 











We have recently generated similar results through an MD simulation in 
collaboration with Alisha Caliman, in the McCammon lab (UCSD), where cocaine 
was docked into the CocE structure (PDB: 3IDA).  Here we found that cocaine 
would move within 3 Å of both residues, with the tropane ring in particular moving 
closest to both residues.  The simulation also showed a hydrophobic interaction 
between the benzoic acid and Phe261 (Unpublished data – Figure 3.15). 
 
 
We began this study hoping to find specific residues that could improve 
the overall efficiency of CocE with the original assumption that interrogating the 
residues nearest the active site, based on the benzoic acid-bound CocE 
structure, might reveal critical residues for catalysis and/or substrate binding.  
Figure 3.15:  Results of Molecular Dynamic simulation done with CocE 
(PDB: 31DA) and cocaine.  Both panels show the interactions between 
Phe261 and benzoic acid portion of cocaine and between Tyr118 and 
unbounded oxygen of benzoic acid.  Ala51 and Gln55 reside in close proximity 
to tropane ring of cocaine.   
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The identification of a novel binding site for cocaine, using a non-hydrolyzable 
cocaine analog in crystallographic studies is striking. The structure of the RTI-
150-CocE complex thus reveals a significantly different potential avenue to 
improve the binding kinetics of cocaine through unraveling a novel cocaine 
docking site.  In particular two residues near the docking site, Ala51 and Gln55, 
when mutated to glutamates, yielded significant improvements in the substrate 
affinity, as indicated by their dramatically lower KM. The importance of these 
residues will be further explored in Chapter 5 of this thesis where the specific 
residues that improve kinetics are tested.  Taking these data together we feel 
extremely enthusiastic that we may indeed be able to improve the catalytic 
constants for cocaine hydrolysis by CocE and that these may translate into 





Table 3.1:  Statistics of crystal structures produced with RTI-150 and WIN 35,065-2. 








Figure 3.16:  Kinetics of binding site mutants  Mutations at residues 51, 55, 169, and 170  The 
kinetics of each mutation discussed in this chapter are shown with their respective Michaelis-Menton 
plots.   
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Crystallographic Study Of Cocaine Esterase’s Catalytic Triad 
 
Introduction 
Enzymes perform most naturally occurring reactions by lowering the 
activation energy required to form a product from a substrate.  The active site of 
an enzyme houses the residues that conduct this chemistry.  One well-defined 
set of residues that make up the active site of hydrolases such as 
acetylcholinesterase, proteases and cocaine esterase, is the catalytic triad of 
aspartic acid, histidine, and serine.  This particular set of residues has evolved in 
enzymes that act on a diverse set of macromolecules, such as proteins, and 
small molecules, like alkaloid compounds[1].   
The three residues that form the catalytic triad need to be in close enough 
proximity in order to transfer a proton from one R-group to another (Figure 4.1).  
The enzymatic mechanism includes abstraction of a proton from histidine by the 
neighboring aspartic acid.  This initial proton abstraction includes polarization of 
histidine such that it allows the imidazole R-group of histidine to form a temporary 
bond with the proton of the hydroxyl of the serine side chain.  By abstracting the 
proton away from serine, the oxygen of serine’s hydroxyl group becomes a good 
nucleophile.  The serine can now target a carbonyl carbon of the substrate for 
nucleophilic attack.  Covalent attachment of the serine to the substrate becomes 
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the first tetrahedral intermediate formed between enzyme and substrate.  This 
intermediate is resolved by abstraction of the proton from histidine, and the 
subsequent release of the first partial product follows.  At this point, the histidine 
is able to abstract another proton from a molecule coordinated in the active site 
(H2O in the case of hydrolases) and stabilize the nucleophile for attack on the 
carbon bound to the acyl-enzyme intermediate attached to the serine.  After this 
second nucleophilic attack a second tetrahedral intermediate is formed and 
typically stabilized by an oxyanion hole on the enzyme.  This intermediate is 
subsequently resolved by flow of electrons from the oxygen on carbonyl carbon 








Intermediate + product 1 
Covalent acyl-enzyme 






+ product 2 
Figure 4.1:  Enzymatic activity of a catalytic triad. Adapted from Wikipedia 
(https://en.wikipedia.org/wiki/Catalytic_triad) by Thomas Shadfee 2014. 
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The attachment of serine to this carbon is destabilized and the serine abstracts 
the proton on histidine allowing for partial product release[1].    
Cocaine esterase performs the same reaction mechanism on cocaine 
through its catalytic triad consisting of Asp259, His287 and Ser117.  Mutations of any 
of these residues renders the enzyme inactive[2].  Though we know which 
residues are responsible for the hydrolytic activity of CocE, we have not 
established a clear role for the residues surrounding the active site nor have we 
studied the movement of active site residues during hydrolysis.  The later 
phenomenon is also an important aspect of enzyme function[3].  More 
specifically, researchers were able to follow the movement of the active site 
histidine of an α/β-hydrolase during hydrolysis as the enzyme move from an 
“open” to “closed” conformation.  Here the open conformation of the protein 
exists when substrate is not bound to the enzyme, and upon substrate binding 
the enzyme adopts a closed conformation that accompanies a shift in the 
position of the active site histidine, presumably allowing the hydrolysis reaction to 
follow.   
Having a structure for each step in the enzymatic pathway would provide a 
more thorough description of the residues that coordinate substrate and product 
and the position of each member in the catalytic triad during hydrolysis of 
cocaine. Fortunately, a couple structures of CocE trapped in intermediate and 
product-bound states have been reported and are available.  The original crystal 
structure of CocE captured a partial product trapped in the active site, modelled 
as benzoic acid[4]. The structure reveals a hydroxyl group of benzoic acid that is 
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coordinated by interactions with Trp166 and Tyr44 and by the amide in the 
backbone of Ser117(PDB: 1JU4 - Figure 4.2 A).  This structure also offered the 
first information on the orientation of the catalytic triad.  Interestingly, the active 
site serine is positioned away from the partial product.  They also found a water 
coordinated precisely between active site Ser117, His287, and Asp259.  By soaking 
the CocE crystals in phenyl boronic acid, the group produced a structure of a 
tetrahedral intermediate bound to Ser117 (PDB: 1JU3 - Figure 4.2 B).  This 
structure reveals a 120° rotation of the Ser117 sidechain away from the position 
where it was found the benzoic acid-bound structure.  During covalent 
attachment of the tetrahedral intermediate, the serine presumable undergoes a 
rotation of about 110-120° into position where the bound phenyl boronic acid can 
occupy a space near where the benzoic acid was shown to occupy.  The catalytic 
triad histidine revolves ~57° away from the product, but the nitrogen of its 
imidazole ring still coordinates with one hydroxyl of the phenyl boronic acid.  The 
other hydroxyl of boronic acid is positioned approximately where the hydroxyl of 
the benzoic acid was, coordinated by Trp166, Tyr44, and the backbone amide of 
Ser117.   
 
107	  
During a crystallographic analysis of CocE generated in our lab, we were 
able to produce another covalently bound molecule with similar but distinct 
aspects to the phenyl boronic acid-bound intermediate structure[5].  This 
structure reveals a DTT adduct bound to Ser117 (PDB: 3I2K – Figure 4.2 C). DTT 
was included in the protein purification procedures and during crystallogenesis in 
order to prevent non-specific disulfide bonding or oxidation of the cysteine 
residues on CocE.   
In both structures, the serine residue adopts a similar position as found in 
1JU3, projecting away from other active site residues.  The dioxolane ring 
structure of DTT sits in the similar plane as the phenyl boronic acid.   
These structures demonstrate the importance of several residues that 
could interact with products.  Other than the residues mentioned above, 
structures PDB:1JU3 and PDB:1JU4 show that Phe261, Leu407 and Phe408 all 
coordinate the ring structure of benzoic acid through hydrophobic interactions.  
Comparison of these structures with apo-CocE structures also reveal the 








A) B) C) 
Figure 4.2: Structures of the active site of CocE in a complex with 
products or acyl intermediates. A) Structure CocE bound to benzoic acid 
(PDB:1JU4), B) Structure of CocE bound covalently to phenyl boronic acid 
(PDB:1JU3) and C) CocE bound as and adduct to DTT (PDB: 3I2K, Brim et al 
2009).  A) and B) were taken from Larsen et al 2002.	  
108	  
structures provide evidence of how CocE’s residues interact with product, we still 
need to analyze how the intact substrate binds prior to hydrolysis.   
To that end, we set out to gather structural information for how cocaine 
binds to CocE using x-ray crystallography.  To address this question we take two 
approaches to trap components in the active site of CocE: 1) an enzyme bound 
to a non-hydrolysable tropane analog of cocaine; or, 2) an inactive enzyme with 
cocaine bound in the active site.  Chapter 3 of this thesis described the results of 
the first approach through delineating a high-resolution structure of CocE 
structure bound to non-hydrolyzable cocaine analog RTI-150.  The structure 
identified a novel docking site quite distal from the active site (>8Å away), as 
define by the benzoic acid and phenyl borate-bound structures.  More 
interestingly, analysis of this site by mutagenesis suggests that this novel site is 
important for cocaine binding and hydrolysis.  This chapter (Chapter 4) describes 
the crystal structure of an inactive mutant of CocE co-crystalized with cocaine, or 
unexpectedly metabolites thereof.  
As stated previously, we realize that the high enzymatic activity of CocE 
would prohibit us from merely soaking cocaine into a crystal of CocE, even when 
it is trapped in a crystal.  Therefore, we designed point mutants at each of the 
residues in the catalytic triad in the active site, and sequentially generated 
mutants Ser117Ala, Asp259Asn, and His287Ala.  Using these inactive mutants, we 
hoped to arrive at a structure of cocaine bound in CocE’s active site.  With such a 
structure in hand we could determine which residues interact with the substrate, 
and use this information to help us understand the substrate-binding portion of 
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the CocE’s KM value[6].  Here, models of CocE bound to substrate or product 
could be analyzed through interrogating interacting residues by mutagenesis and 
their enzymology.  The models could be validated or altered depending on the 
enzymatic behavior the new mutations, and any mutations that show an 
improvement to CocE kinetics could be employed towards our long-term goal of 




Generation of CocE:  The enzymatically dead mutants of CocE were generated 
using a variation on the Quick-Change method for site-directed mutagenesis 
mentioned previously [5]. Oligonucleotide primers for Ser117Ala, Asp259Asn and 
His287Ala were synthesized by Integrated DNA Technology (La Jolla, CA) with 
sequences: Ser117Al= 5’- TTC GCG TTG CCT ACT TGG GTG –3’; Asp259Asn = 
5’- GGG TGG TAC AAC GGG TTC GTC G-‘3; and His287Ala = 5’-CCT TGG AGT 
GCC AGC AAC CTC-3’. For the active site mutations, oligonucleotide primers for 
Y118A: 5'	  -­‐	  C	  GGC	  GTT	  TCG	  GCG	  TTG	  GGT	  GTG	  -­‐	  3';	  Y118F:	  5'	  -­‐	  C	  GGC	  GTT	  TCG	  TTT	  TTG	  
GGT	  GTG	  -­‐	  3';	  M141A:	  5'	  -­‐	  GCG	  CCG	  TCC	  GCC	  GCG	  TCG	  GCG	  -­‐	  3';	  and	  S288T:	  5'	  -­‐TGG	  AGT	  
CAC	  ACC	  AAC	  CTC	  AC	  -­‐	  3'	  were	  ordered	  from	  Integrated	  DNA	  Technology	  and	  used	  in	  a	  
PCR	  with	  the	  CC-­‐CocE	  gene	  as	  template	  for	  the	  reaction.	  	  	  
Following site-directed mutagenesis the gene encoding CocE was 
expressed from pET-22b (+) plasmid in BL21 (DE3) (Novagen) bacterial cells.  
Cells were grown to OD600 = 0.6 AU, temperature-shifted to 18°C, and protein 
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expression was initiated with the addition of 1mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Genesee Scientific).  Expression continued for 16 
hours, and cells were pelleted and stored at -80°C until purification.  The cell 
pellet was resuspended in 1X Tris-buffered saline (TBS) in the presence of 
protease inhibitors limabean trypsin inhibitor and leupeptin and broken with two 
passes through a French Press.  (ThermoScientific)  Bacterial lysate was clarified 
by centrifugation at 25,000 x g  and loaded onto a Ni2+NTA column equilibrated 
with 1 x TBS at pH 7.4.  The protein was eluted using 1 x TBS with 150 mM 
imidazole.  Protein dimers were covalently cross-linked by incubating with 50 µM 
CuCl2 at 4°C overnight.  The entire reaction was loaded onto a Q-sepharose 
column equilibrated with 50 mM Tris, pH 8.0 and eluted with linear NaCl gradient.  
Peak fractions were analyzed with SDS-PAGE, pooled and concentrated to 10 
mg/ml with Amicon concentrators (Millipore) and stored at -80°C.  	  
 
Generation of Crystal Structures:  CocE crystals were grown by hanging drop 
vapor diffusion in 24-well VDX trays (Hampton Research).  One microliter of 
protein (either inactive Asp259Asn or His287Ala, or RQ-CocE with saturating 
concentrations of cocaine) and well solution (PEG/MES/NaCl) were mixed on 
siliconized glass coverslips (Hampton Research) and placed over 1 ml of well 
solution.  Trays were incubated at 12°C and crystal growth was observed after 2-
3 days.  Crystals were harvested and placed in cryoprotectant (well solution 
supplemented with 20 % glycerol) and flash-frozen in liquid or alternatively 
crystals were soaked in cryoprotectant containing saturating solution of either 
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cocaine allowed to incubate at room temperature for 5 minutes. Crystals were 
mounted on proper sized loops (0.2 – 0.4 µm – Hampton Research) and flash 
frozen in liquid nitrogen.  X-ray diffraction data were collected at the Advanced 
Photon Source.  Data were integrated and scaled using HKL2000[7].  Molecular 
replacement using Phaser was run using PDB:3IDA as the search model.  
Successive rounds of refinement were performed using Phoenix software [8] and 
manual fitted using Coot [9].   
 
Cocaine esterase activity assays: Cocaine assay:  Purified PEG:CocE was 
analyzed using our standard absorbance-based cocaine assay, described 
previously[10]. Here, cocaine (Mallinckridt, Hazelwood, MO) is added a 96-well 
UV-permeable plate (Costar; Corning Life Sciences, Lowell, MA) at 200, 100, 50, 
25, 10, 5, 1 and 0.5 µM concentrations. The reaction is initiated by the addition of 
PEG:CocE (65 ng/ml) at a 1:1 dilution in the plate. The velocity of the reaction 
was measured every 10s for 20 minutes by a SpectraMax Plus 384 UV plate 
reader (Molecular Devices, Sunnyvale, CA) using SOFTmax Pro software 
(version 3.1.2).  The absorbance readings were converted to change in 
concentration of product using using Beer’s law.  The specific activity of the 
enzyme was plotted using Prism software (GraphPad Software Inc., San Diego, 








Crystal structure from inactive CocE cocrystallized with cocaine:  After 
expression and purification of the Ser117Ala, Asp259Asn and His287Ala CocE 
mutants, an enzymatic assay was performed using cocaine as the substrate and 
confirmed that no measureable activity based on the absorbance assay could be 
detected (data not shown).  
While no crystals were obtained with the Ser117Ala mutant in co-
crystallization attempts, nor were any satisfactory diffraction data sets collected 
on the Ser117Ala crystals soaks, we were able to generate good data sets with 
the crystals of Asp259Asn and His287Ala CocE.  The resolution limit of Asp259Asn 
was 1.8 Å, and the limit for His287Ala was 2.6 Å.  The data contained two 
monomers per asymmetric unit as seen in previous CocE structures generated 
under similar conditions.  The refinement statistics are detailed in Table 4.1.  
 The model generated from these data showed a distinct electron density 
around Ser117 in the active site (Figure 4.3) that resembles the density found for 
benzoic acid-bound structure (PDB:1JU4) rather than the much larger substrate 
cocaine.  It thus appears, based on the electron density that we have trapped a 
molecule of benzoic acid in the active site, puzzling since the enzyme is a 
confirmed catalytically inactive mutant.  Careful comparative analysis of this 
novel structure with PDB:1JU4 reveals subtle but distinctly structural different in 
the position of the benzyl ring (tilt angle), the residues that compose the catalytic 
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triad, and the presence of a strong density consistent with a deprotonate water, 
(OH-) near Ser117.  Similar to the benzoic acid-CocE structure Phe261, Leu407, and 
Phe408 all sit within 5 Å of the phenyl ring of the product.  These residues have 
become important in our next study attempting to generate a more efficient CocE 
enzyme.  (Chapter 5 of this thesis) 
 The most obvious difference between the two structures is the continuous 
electron density found between the benzoic acid and the Ser117 side chain the 
rotomeric angle of the serine and the proximity of the benzoic acid to the Ca 
carbon of Ser117 (See Figure 4.3).  These features are consistent with a covalent 
intermediate of benzoyl moiety bound to Ser117. 
 
 Looking at the active site residues, we see the most dramatic shift in 
His287 (Figure 4.4).  Analysis of these structures reveal that His287 is within 
hydrogen bonding distance to Asp259 in the transition state intermediate modelled 
Figure 4.3:  Covalent intermediate attached to Ser117  Electron density 
present after co-crystallizing Asp259Asn with cocaine.  Purple mesh represents 
composite omit map generated at 1.8 Å shown at 3 σ.  Right panel contains 




from phenylborate-bound CocE structure (PDB:1JU3).  However, following 
hydrolysis to product benzoic acid the side chain of His287 appears to lose it’s 
hydrogen binding to Asp259 and rotates away(PDB:1JU4).  His287 in our structure, 
which contains the covalent acyl-enzyme intermediate, resembles more of the 
benzoic acid structure, and rotating toward the neighboring Ser288.  
Accompanying this rotation away from Asp259 is 180° flip of the imidazole ring 
where the N-1 (pros –	  π) nitrogen appears closer to Ser288 and more importantly 
the N-2 (tele – τ) nitrogen is close to the oxyanion of the benzoyl moiety.  
 
 
 To further investigate the position of active site residues, several residues 
were selected for mutation.  Two residues directly downstream of active site 
residues were chosen, Tyr118 and Ser288, based on the movement of Ser117 and 
His287, respectively.  Also, methionine at position 141 was chosen due to its 
orientation above the active site, showing potential to influence both substrate 







Figure 4.4: Rotation of His287 during catalysis.  Illustrated is the position of 
His287 bound to phenylboronic acid (green, PDB:1JU3), benzoic acid (grey, 
PDB:1JU4), or as an acyl-enzyme intermediate (fleshtone).  Indicated is the 
distance (Å) between the imidazole ring of His287 and the oxalate of Asp287. 
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Analysis of CocE active site mutants 
Table 4.2  Catalytic constants of substitutions of Tyr118 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency      (µM-
1•min-1) 
Tyr118Ala >400 6500* NC 
Tyr118Phe 42 +/- 13 370 +/- 50 8.7 
* note that this value is insignificant since the Km> concentrations of cocaine used in the assay 
 
Tyr118:  Tyr118 sits at the N-terminus of alpha helix C in domain I.  This residue is 
not close enough to substrate to interact with the molecule, but its proximity next 
to the active site serine (Ser117) and could influence the hydrolysis of cocaine by 
CocE.  As stated above, CocE belongs to the α/βhydrolase superfamily of 
proteins, and as such, contains a slight variation of the GXSXG motif surrounding  
 
the active site serine.  In CocE, the sequence around Ser117 reads GVSYLG, 






Figure 4.5: CocE residue Tyr118.   The left panel shows the native residue Tyr118 
positioned near the active site and possibly interacting with the tropane ring.  The 
middle panel displays mutant Tyr118Ala whereas the right panel contains position of 





Both mutations generated at position 118 produced enzymes that were 
virtually inactive.  The Tyr118Phe mutant retained some activity with a KM that is 
almost twice that of our control CocE kinetics, but the Vmax of this mutant dropped 
to only 370 min-1.  By retaining the aromatic group of tyrosine with the 
phenylalanine mutation, the enzyme could retain the overall structure at this 
position but apparently lost its ability to hydrolyze substrate in an appreciable 
manner.   
The Tyr118Ala mutant showed almost no capacity to hydrolyze cocaine due 
to it’s undeterminable Km. We interpret the removal of the aromatic ring as 
removing a major component of the interaction with the tropane ring of cocaine 
and thus removing a major interaction surface resulting in dramatic decreases in 
substrate binding affinity. As a result of the deficit in substrate binding affinity to 
the point where the conditions of our absorbance assay could not accurately 
determine the Vmax, nor overall catalytic efficiency (NC).   
 
Met141:  Met141 sits at the C-terminus of the β6 strand, in a loop region that 
connects DOM1 and DOM2.  Since it is positioned within 4 Å of two active site 
residues, Ser117 and Asp259, so it has potential to influence the orientation of 
these two residues during enzymatic activity.  This residue was also chosen due 
to its position in proximity to an active site water modeled in to the density map in 
1JU3 and our maps with the RTI compound.  Our reasoning was that by 
increasing the hydrophobicity of this pocket, excluding water, the D259 would 
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become more acidic and increase proton transfer to S117, and therefore increase 
overall velocity of the enzyme.   
Mutation from methionine to alanine was a first step in exploring the 
hydrophobic effect at this position.  Though alanine does not have the overall 
density of methionine, we reasoned that an alanine would provide a more 
structured hydrophobic presence and potentially hold help exclude waters.  The 
results suggest that decreasing the size of the residue has only hindered the 
ability of cocaine to bind, increasing the overall KM, and also disrupting chemistry 
in the active site, decrease in Vmax.  Mutating to a larger hydrophobic residue 
(isoleucine or phenylalanine) will provide a larger hydrophobic density that might 
support our initial positing of how the hydrophobic effect can increase active site 




























Figure 4.6:  CocE residue 141  Left panel shows residue Met141 in proximity 
to the catalytic triad.  Right panel shows hypothetical positioning of Ala141 
mutant.   
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Table 4.3:  Kinetics of CocE mutant – M141A 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency 
(µM-1•min-1) 
M141A 110 +/- 30 580 +/- 98 5.4 
 
Ser288Thr:  The long loop region connecting the β8 and β8a strands of DOM1 
contains Ser288 (Figure 4.7)  We believe that the R-group of this residue sits in 
close enough proximity to His287 for it to influence the positioning of the imidazole 
group and therefore the overall chemistry.  We chose threonine as the residue to 
replace serine so that the hydroxyl presence is preserved, but the increased size 
of the R-group may provide crowding to bring the His closer to the ester bond 
being hydrolyzed, and expedite resolution of the tetrahedral intermediate.   
 
 
Table 4.4:  Kinetics of CocE mutant – Ser288Thr 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency 
(µM-1•min-1) 
Ser288Thr 31 +/- 9.0 4800 +/- 54 154 
Figure	  4.7	  	  CocE	  residue	  288	  	  Left	  panel	  shows	  position	  of	  Ser288	  next	  to	  His287	  




























This mutant showed some of the best kinetic improvement of all mutants 
tested.  The velocity increased almost two-fold, and the change in KM although 
only slightly elevated is better than some of our most thermostable mutants.  The 
overall catalytic efficiency, therefore is improved almost 50% above our highest 
activity mutant (KQ-CocE).  We hypothesize that this increase in Vmax is due to a 
more optimized positioning of His, as stated above and will be elaborate in 




Finding the benzoic acid covalently attached to Ser117 in the Asp259Asn, 
rather than the substrate cocaine bound to this catalytically inactive enzyme, was 
an unexpected result.  The intention was to obtain the structure of CocE bound to 
cocaine using a catalytically inactive mutant.  Removing the acidic residue 
(Asp259) from the catalytic triad should disrupt the orientation of the histidine 
residue, and presumably not allow the initial nucleophilic attack of the Ser117 on 
the substrates ester carbonyl carbon due to the imidazole group of His287 not 
abstracting the proton from Ser117.  The role of Asp259 is normally to help stabilize 
the base (His287) in its protonated form until it can donate the proton to the 1st 
product (Figure 4.1).  Though the mutants showed no activity when assayed, the 
Asp259Asn mutant still possessed enough energy to promote a “half-turnover” 
style chemistry that allowed the first tetrahedral intermediate to form and then be 
resolved, thus releasing one mole of ecgonine methylester per mole of enzyme.    
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Interestingly, a strong electron density is found in the acyl-enzyme 
intermediate structure located just above the ether linkage on Ser117 (Figure 4.8).  
This strong density is too large to be a cation and extremely well ordered.  It is 
also located at the same position of as one of the hydroxyls of phenyl boronic 
acid bound to CocE as a tetrahedral intermediate.  We therefore surmise that the 
density may represent a hydroxyl (OH-) poised for nucleophilic attack of the 
carbonyl of the benzoyl moiety of acyl-enzyme intermediate.   It is not clear how 
the OH- is stabilized since the proton-accepting capacity of His287 was 
compromised the Asp259Asn mutation.  A likely explanation is the presence of 
Tyr44 positioned directly above the active site and pointing directly at the putative 
OH-.  Note that a Tyr44Phe is catalytically inactive [4]. 
 
 
The reaction mechanism for resolving the second tetrahedral intermediate 
involves activation of a water molecule by proton abstraction by histidine.  Upon 
Figure 4.8 Trapping the attacking OH- in the Acyl-enzyme intermediate 
structure. A) a strong electron density (circled in blue) was located above the 
Ser117-benzoyl ester. B) the strong density superimposes on the OH- of phenyl 
borate-CocE in the tetrahedral intermediate structure (PDB: 1JU3).  C) the 






















activation, the water can perform a nucleophilic attack on the carbon covalently 
attached to Ser117.  His287 is capable performing the proton abstraction after it is 
coordinated by an active site aspartic acid (Asp259). In our structure, the reaction 
appears to have halted after the release of the first product, EME, and the 
enzyme is attenuated in the covalent acyl-enzyme intermediate step (Figure 4.8).  
It therefore appears that the His287 coordination by Asp259 is only necessary for 
resolving the second covalent intermediate.  
We hypothesize that this model is supported by our covalent intermediate 
structure in terms of how the His287 residue is positioned away from the active 
site.  As described above, the active site histidine resides similar to that found in 
the tetrahedral intermediate structure in 1JU3.  Since this histidine is shifted 
away from the active site, the proton abstraction from the active site water could 
be attenuated and therefore final resolution of the second tetrahedral 
intermediate prohibited. 
The position His287 in the RTI-150 containing structure provided another 
half step in generating a model of CocE’s mechanism of hydrolysis.  Considering 
each structure covered so far, the imidazole ring of His287 resides in one of two 
positions: 1) with the π-nitrogen of imidazole facing the active site, or 2) with the 
same nitrogen facing away from the active site.  The residue will shift 
approximately 3 Å in the same plane towards or away from the active site, but 
the aforementioned rotation is the greatest movement seen in this residue.  
His287 of the RTI-150 structure is the only result showing the ring portion out of 
plane, perpendicular to the histidine of all other CocE structures.  Though we can 
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only speculate towards a reason, we know that this structure is not a completely 
ligand-free, or apo, structure.  While there is no substrate or product in the active 
site, there is a putative substrate bound to the enzyme.  The perturbation of this 
substrate binding may be shifting the histidine towards the active position, where 
it is ready for proton abstraction from the serine residue that will initiate chemistry 
of hydrolysis.   
In this study, several mutants were generated to investigate repositioning 
the active site residues.  The Michaelis-Menton plot of enzyme assays is 
summarized in Figure 4.10.  Both mutations to Tyr188 altered CocE activity by 
either completely disrupting cocaine binding (Tyr118Ala) or by reducing chemistry 
to a Vmax almost a full order of magnitude lower compared to a fully active 
enzyme (Tyr118Ala).  Presumably, taking away the van der Waals contacts of the 
phenyl ring in the alanine substitution opens the active site up so that substrate 
can’t bind with an appreciable affinity.  Note that the high Vmax value in this 
mutant is therefore a projected value with little significance since the Km 
estimates are beyond the limits of the assay.  Alternatively, by removing the 
hydroxyl of tyrosine, leaving the phenylalanine, the substrate is able to bind 
(demonstrated by slightly perturbed KM of 40 µM) and chemistry occurs albeit at 
a much-reduced rate.   
The Met141Ala mutation was viewed as a “whole system” perturbation due 
to how the R-group of methionine sits across the active site, and shows potential 
to influence positioning of active site residues and substrate alike.  The results of 
this mutation demonstrate exactly that.  By removing the bulky R-group, the KM 
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reduced by over 4-fold and the Vmax lost an order of magnitude in value.  Thought 
we cannot explain the results through the effect on substrate or active site 
coordination, by affecting all aspects of the kinetics, this mutation shows the 
importance of this residue.  Future studies could focus on using different residues 
to see if a more optimal mutation exists.   
 Perhaps the most interesting mutation is the Ser288Thr substitution as it 
provides improvement to only the velocity.  Looking at the structures, by placing 
a bulkier residue in place of serine, eg. a methyl group of a threonine residue, but 
keeping the hydroxyl presence, we may have positioned the His287 in the position 
closest to the active site residues as demonstrated from the various structures in 
Figure 4.4.  A more thorough discussion of this mechanism is discussed in the 
following chapter (Chapter 5). 
This new acyl-enzyme intermediate structure has now allowed us to 
generate a more complete snapshot of the enzymatic reaction of cocaine 
hydrolysis by CocE.  The structural data along with site-directed mutagenesis 
studies have helped to delineate the contributions of many of the residues 
surrounding the catalytic sites.  Below is a pictorial summary of the structural 
information now available to our laboratory presented in sequentially ordered 
fashion to reflect the reaction coordinate of cocaine metabolism by cocaine 
esterase (Figure 4.9).  
Since we are trying to generate a more efficient CocE enzyme, we 
hypothesize that this new structure could significantly help in our enzyme 
engineering efforts.  Three residues look to be in close enough proximity to have 
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hydrophobic interactions with the phenyl ring of benzoic acid.  Phe261 and Phe408 
along with Leu407 all have potential to interact with the benzoic acid product.  
While interpreting the results of the Larsen et al study, we reasoned that they 
found benzoic acid trapped in the active site due to the failure of the enzyme to 
release this final partial product.  Our structure shows which residues may be 
interacting with the benzoic acid as well as provides the pivotal information to 
help us understand the catalytic mechanism.  We hope to use these data as well 
as the spectacular new date in Chapter 5 which describes the existence of an 
additional binding site, a docking site, for the substrate cocaine.  The 
identification of mutants described here and mutants described and 
characterized in Chapter 5, which were all based on novel crystallographic data 
on CocE, will provide multiple templates for engineering enzymes with improved 
catalytic constants and improved overall catalytic efficiency. 
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Figure 4.9 Structural representation of chemistry of cocaine hydrolysis 
by cocaine esterase.  A) The catalytic triad located in the active site of CocE. 
B) Both His287 and Ser117 have to move their side chains (red arrows) to 
accommodate the binding of cocaine, based on the benzoic acid-bound form 
of CocE (PDB:1JU4). C) Acyl His287 may be able to perform limited proton 
donor activity to allow for the nucleophilic attack of the Ser117 side chain on the 
carboxyl ester of cocaine.  The result is the formation of an acyl-enzyme 
intermediate. D) Tyr44 (not shown) helps to deprotonate H20creating a 
nucleophile (OH-) poised to attach the carbonyl of the Ser117-benzyol 
intermediate.  D) rotation of the imidazole ring of His287 toward a more 
productive interaction with Asp259, to aid in stabilizing the protonated state of 
His287.   E) The tetrahedral intermediate, modeled here based on the phenyl 
boronic acid structure (PDB: 1JU3) contains a OH- on the ester-CocE linkage 
at the precise location of the position of the OH- in D).  F) Nucleophilic attack 
of the Ser117 by the OH- releases the product benzoic acid(PDB:1JU4).  As a 
result both the Ser117 side chain and His287 imidazole ring adopt the apo-CocE 
























































Table 4.1:  Statistics of crystal structures produced with D
259
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Figure 4.10  Kinetics of CocE mutants  Single mutations to CocE 
generated in CC background.  All mutations were tested in standard cocaine 
based assay.  Analysis of individual data points covered in respective 
sections in text.   
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 A crucial step in developing an enzyme-based therapeutic is to optimize 
the enzymes catalytic properties.  Treating cocaine addiction, like treating many 
substance abuse-related diseases, requires good patient compliance and thus 
benefits from continuous, on-board therapeutic.  Cocaine esterase, an enzyme 
that efficiently hydrolyses cocaine into inactive metabolites - ecgonine 
methylester and benzoic acid - has demonstrated great potential as a therapeutic 
to treat cocaine addiction through rapidly accelerating cocaine metabolism and 
elimination.  Indeed, a thermostable form of enzyme has been successfully 
tested in humans as an antidote for cocaine intoxication [1].  We have since 
generated several forms of the enzyme with superior thermostability profiles and 
have tested them in models of toxicity in rodents.   
While our current enzyme is arguably the most efficient to date, its actual 
kinetic parameters may not the most desirable for treating cocaine addiction [2].  
Typical circulating cocaine concentrations found in a dosing cocaine addict might 
reach 50 µM in humans [3, 4].  The catalytic properties of our current enzyme 
would dictate that it would require 2-3 grams of enzyme on board to reduce the 
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cocaine to levels that are not physiologically effective, for an average 70 kg male.  
To avoid patient compliance issues and multiple administration protocols they 
formulation must either be stable in vivo for long periods (eg. 1 month), or a 
sustained release formulation would be required.  The limited in vivo lifetime of 
biologics, which in this case is ~48 hours for the best current form of CocE, would 
limit our formulation to the latter, that of sustained release.  A back of the 
envelope calculation would imply that loading a sustained release module, or 
even an osmotic pump, with one months worth of CocE would require 
approximately 30 grams of protein.  Increasing the catalytic efficiency of CocE by 
5-10-fold would reduce that level substantially.   
Moreover, such an increase in enzyme performance would significantly 
reduce the cost of production of the enzyme, something that could be significant 
for the cocaine overdose antidote.  The cost of production of protein-based 
therapeutics is significantly higher than for small molecule drugs.  A 2008 report 
found that the production costs for biologics in the United States is approximately 
$45 per day or $16,425 per year, compared to $2 per-day and $730 per-year for 
more traditional, small molecule pharmaceuticals [5]. Any increase in drug 
efficacy or enhancement of production efficiency will therefore have a profound 
impact on the cost of production.   Though we have optimized protein production 
of CocE in bacteria to gram level quantities in the laboratory and kilogram 
quantities for clinical trial studies, any increase the enzyme efficiency and 
efficacy would have a significant impact on the cost of production.    
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 One of the most straightforward and readily available methods to improve 
enzyme kinetics is through site-directed mutation.  One of our earlier 
thermostable mutant CocE enzymes, Leu169Lys/Gly173Gln-CocE (KQ CocE), 
unexpectently also displayed higher catalytic activity than wild-type [6].  The 
maximal velocity of KQ CocE (6500 min-1 for cocaine) is almost three times 
higher than the CocE mutant currently in clinical trials to treat cocaine addiction, 
Thr173Arg/Gly173Gln-CocE (RQ-CocE,  2500 min-1). 
 While both KQ-CocE and RQ-CocE share the glutamine mutation at 
position 173, mutation of a single residue (L169) seems to confer enhanced 
catalytic properties. Unfortunately the increase in Vmax of KQ-CocE did not 
accompany an overall improvement in the enzymes catalytic efficiency, since an 
increase in KM value is observed.  The differences in the velocites of two mutant 
forms of CocE, is still encouraging, leading us to reason that we could generate 
other mutants with better kinetics through strategic mutation with not only better 
chemistry but also increased rates of substrate binding and/or product release. 
   
 Fortunately, several previous research efforts have laid the foundation and 
starting point for residues to focus on based on how they may interact with 
Figure 5.1: Amino acid sequence alignment of 
CocE mutants  WT, RQ and KQ.  The sequence 
of amino acids depicts the difference between the 
three forms of CocE with WT (top row), KQ 
(middle row), and RQ (bottom row).  Residue 
numbers are listed above each row.    
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CocE’s substrate or product.  The several research efforts that we have used as 
a basis for our study are:   
-­‐ The previously published CocE structure with benzoic acid modeled in 
the active site (PDB: 1JU4) 
-­‐ Our crystal structure CocE containing RTI-150 in the putative 
binding/desolvation site 
-­‐ Our crystal structure of CocE in a transition state covalently bound 
benzoyl intermediate – positioning of the active site triad  
-­‐ The molecular dynamics (MD) simulation of cocaine binding to CocE  
 
In the first structural study of CocE, Larsen et al reported the structure of 
CocE bound to benzoic, as well as the structure of CocE bound to phenylboronic 
acid, as a transition state analog of cocaine [7].  Together these studies provided 
an early model of the catalytic mechanism of cocaine metabolism.  Interestingly, 
in their CocE-benzoic acid structure the authors reported that the benzoic acid 
found in the active site was actually a contaminant in the CocE preparation that 
remained bound during expression, purification and crystallization.  These data 
suggest that the affinity of benzoic acid for CocE is relatively high. Considering 
that benzoic acid is one of two major products of cocaine hydrolysis (benzoic 
acid and ecgonine methyl ester), these data suggest that product release could 
be a limiting step in enzymatic turnover of cocaine.  We thus hypothesized that 
lowering the affinity of benzoic acid would might speed up product release and 
hence increase the Vmax for cocaine hydrolysis.  We thus considered several 
133	  
residues in proximity to benzoic acid in the active site that might diminish benzoic 
acid binding without perturbing substrate binding.  Concurrent with these studies 
we focus on residues that coordinate the tropane portion of cocaine in an attempt 
to enhance substrate affinity.  The combination of either two approaches, 
increasing product release and/or increasing substrate affinity, may contribute to 
lowing the KM for cocaine by CocE.  The goal would be to couple these KM 
mutants with Vmax mutants like KQ-CocE and enhance the catalytic efficiency. 
(Figure 4.1A)   
Building off of the model containing benzoic acid, we performed a 
hypothetical modeling of how cocaine may sit in the active site.  Positioning the 
benzoic acid over the partial product from the Larsen structure and then 
positioning the rest of the ecgonine methylester (EME) where it looks to be 
favorable, we were able to target several other residues that may influence the 
binding of cocaine or release of the EME. (Figure 4.1B)   
Substrate binding site: 
As described in Chapter 3, one of our attempts to generate a model for 
how cocaine binds to the active site includes using a non-hydrolyzable cocaine 
analog in an active CocE enzyme.  To that end, we used two tropane-containing 
molecules (WIN 35,065-2 and RTI-150) without internal esters in a 
crystallographic study that produced a structure for each molecule with 1.8 Å 
resolution.  Both analogues bind and inhibit CocE.  The density corresponding to 
RTI was modeled into an electron-rich density, near where we had initially 
positioned cocaine.  Surprisingly the position of the ester bond linking benzoic 
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acid to the tropane ring is approximately 11.5Å away from the active site serine.  
We therefore reasoned that location of RTI binding suggested by crystal structure 
might serve as a “docking site” where cocaine binds prior to moving into the 
active site.  Several residues within hydrogen bonding distance to RTI in the 
“docking site” were subsequently mutated to interrogate each specific residue’s 
influence on CocE kinetics.   
Previous studies using MD simulation suggests that alanine at position 51 
and glutamine at position 55 stabilize binding of the tropane ring of cocaine[8].  
Furthermore, the investigators hypothesize, but did not test, that a glutamate 
substitution at this position might increase the interaction with substrate, due to 
hydrogen bonding between the nitrogen in the tropane ring and the acidic 
carboxyl side chain of glutamate, thus decreasing the KM of the overall CocE 
kinetics[8]. In a collaborative effort with the Laboratory of Dr. Andrew 
McCammon, here at UCSD, we performed a similar course-grain MD simulation 
with cocaine and converged on a similar mechanism whereby the tropane ring of 
cocaine spontaneously moves within 3Å of both Ala51 and Gly55.  (Caliman, 
unpublished results). 
Active site mutants and the catalytic triad: 
Chapter 4 described our structure of the benzyl alcohol-bound CocE using 
the Asp259Asn mutant likely represents the first transition state of cocaine 
hydrolysis by CocE.  Below we summarize the involvement of the residues that 
form the catalytic triad (Asp259, His287 and Ser117) and the proposed catalytic 
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mechanism in order to frame the selection and participation of candidate mutant 
residues that may alter catalysis.   
Illustrated below is a cartoon of the catalytic triad of a CocE in relation to 
substrate cocaine.  Highlighted are the catalytic residues Asp259, His287 and 
Ser117 representing the acid, base and nucleophile, respectively, that are directly 
involved in the catalysis.  The active site mutations below were designed with this 
classic catalytic triad of an esterase in mind but in the context of the various 
CocE structures now available to our laboratory.  Here, His287 serves as the base 
first involved in first polarizing (ie. accept a proton) the nucleophile (OH of Ser117) 
where it may attack the carbonyl carbon off the benzoyl moiety of cocaine and 
release the negatively charged ecgonine methyl ester.  His287 is then 
deprotonated by ecgonine methyl ester.   This nucleophilic attack results in the 
first transition state (TS1) and is depicted by our transition state structure 
described in chapter 4.  Following stabilization of the base (His287) by the acid 
(Asp259) an incoming H2O becomes the second nucleophile following 
deprotonation.  The nucleophilic attack by the OH- on the carbonyl carbon of TS1 
releases yielding a tetrahedral second transition site (TS2), a structure closely 
resembling the phenylboronic acid-bound CocE structure (PDB: 1JU3).  Finally, 
the protonated His287 donates its proton to the leaving group, in this case the 
oxyanion of Ser117, and thus the release of benzoic acid. as the leaving group 
leaving and protonating the O- of the ecgonine methyl ester. 
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 With this mechanism in mind and utilizing the available structural 
information we propose to test whether mutations in surrounding residues may 
alter the structure of members of the catalytic triad and enhance catalytic activity. 
Based on structures of the RTI-150-bound CocE and the transition state 
analog described in Chapters 3 and 4, respectively, we have identified several 
residues that may influence the binding and hydrolysis of cocaine in CocE.  
(Figure 4.2B)  Using site-directed mutagenesis we test whether residues in the 
wild-type or KQ-CocE (both in the thermostabilized Gly4Cys/Ser10Cys-CocE) 
background that could increase or decrease their hydrophobicity or alter local 
charge density to the point that either product release is accelerated or substrate 
binding (KM) is enhanced.  The list of residues surveyed in this study, including 
the rationale for selecting the location of the mutant as well as the substitution is 




Site-directed Mutagenesis:  Oligonucleotides (IDT, San Diego, CA) were 
designed based on the crystal structure of the thermostable mutant CCRQ-CocE 
[9] and used in a modified Quickchange™ protocol (Stratagene, La Jolla, CA) to 
replace a specific codons in the CocE nucleotide sequence.  Oligonucleotides 
targeting residues:  F261A: 5'-­‐	  G	  TAC	  GAC	  GGG	  GCG	  GTC	  GGC	  GAA	  TC	  -­‐3';	  F261W:	  5'	  -­‐	  
TAC	  GAC	  GGG	  TGG	  GTC	  GGC	  GAA	  TCG	  -­‐	  3';	  L290W:	  5'	  -­‐	  CAC	  AGC	  AAC	  TGG	  ACT	  GGT	  CGG	  
-­‐	  3';	  L407A:	  5'	  -­‐	  GGG	  ACG	  CTG	  GCC	  TTC	  CAC	  AAC	  -­‐	  3';	  F408A:	  5'	  -­‐	  ACG	  CTG	  CTG	  GCC	  CAC	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AAC	  GGA	  G	  -­‐	  3';	  F408Y:	  5'	  -­‐	  ACG	  CTG	  CTG	  TAT	  CAC	  AAC	  GGA	  G	  -­‐	  3'	  were	  ordered	  from	  
Integrated	  DNA	  Technologies	  (La	  Jolla,	  CA).	  	  Codons in bold print represent the 
target residue.  We utilized bacterial expression vectors (pET22b) containing the 
thermostable mutant of CocE, CC-CocE, as a template for the mutagenesis 
studies [9].  The expressed protein has a Hisx6 tag at the carboxy-terminus to 
facilitate protein purification.  Sequences for all mutant plasmids were confirmed 
by DNA sequencing. 	  
 
Production of CocE proteins:  The mutant forms of CC-CocE were expressed 
from pET-22b (+) plasmid in BL21 (DE3) (Novagen) bacterial cells.  Cells were 
grown to OD600 = 0.6 AU, temperature shifted to 18°C, and protein expression 
was initiated with the addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(Genesee Scientific).  Expression continued for 16 hours, and cells were 
pelleted, flash frozen in liquid N2 and stored at -80°C until purification.  The cell 
pellet was resuspended in 1X Tris-buffered saline (TBS) and broken with two 
passes through a French Press (ThermoScientific).   Bacterial lysates were 
clarified by centrifugation at 25,000x g and loaded onto a Ni2+NTA column 
equilibrated with 1 x TBS at pH 7.4 @ 4°C supplemented with protease inhibitors 
(PIs) (3 mg/mL each of leupeptin and lima bean or soybean trypsin inhibitor).  
The protein was eluted using 1 x TBS with 150 mM imidazole and PIs.  To 
facilitate disulphide crosslinking of the CocE protomers  and stabilization of the 
CocE dimer the elute fractions were treated with 50 µM CuCl2 at 4°C overnight.  
The entire reaction was loaded onto a Q-sepharose FPLC column equilibrated 
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with 50 mM Tris, pH 8.0 @ 4°C  and PIs.  CocE protein was eluted off with a 
linear gradient in a buffer containing 50 mM Tris, pH 8.0 @ 4°C, 1M NaCl and 
PIs.  Peak fractions were analyzed with 10 % SDS-PAGE, pooled and 
concentrated to 10 mg/ml with Amicon concentrators (Millipore), flash frozen in 
liquid N2 and stored at -80°C. 
 
Cocaine-based activity assay:  The catalytic activity of purified CCRQ-CocE 
mutants were analyzed using our standard absorbance-based cocaine assay, 
described previously [10].  Here, cocaine (Mallinckridt, Hazelwood, MO) is added 
a 96-well UV-permeable plate (Costar; Corning Life Sciences, Lowell, MA) as a 
2X solution at 200, 100, 50, 25, 10, 5, 1 and 0.5 µM concentrations in a buffer 
containing 50 mM Tris-HCl, pH 8.0 @ RT. The reaction is initiated by the addition 
of PEG:CocE (65 ng/ml in 50 mM Tris-HCl, pH 8.0 @ RT) at a 1:1 dilution in the 
plate. The velocity of the reaction was measured every 10s for 20 minutes using 
a SpectraMax Plus 384 UV plate reader (Molecular Devices, Sunnyvale, CA) 
using SOFTmax Pro software (version 3.1.2).  The absorbance readings were 
converted to change in concentration of product using Beer’s law.  The specific 
activity of the enzyme was plotted using Prism software (GraphPad Software 









Residues targeted for enhanced catalytic properties by mutagenesis:  The list of 
residues targeted in this study can be found mapped on the structure of CocE 
(Figure 5.2).  The mutants have been organized into three different categories:  
active site mutants, substrate binding site mutants, and putative docking-site 
mutants.  The active site mutants were chosen for their proximity to the active 
site residues themselves or by their potential to alter positioning of the catalytic 
triad residues and influence substrate binding or chemistry.  These residues 
include Tyr118, Met141, and Ser288 and their mutation is covered in Chapter 4.   
Figure 5.2: Position of all residues mutated on CocE.  A) Location of the 
active site mutant residues mapped on the model of cocaine-bound CocE.  
Side chain residues are rendered as spheres and cocaine (magenta) is 
depicted as a stick figure. B) Close-up of A) highlighting the active site 
residues.  Cocaine is modelled in the active site of CocE based on the 
structure of benzoic acid-bound CocE (PDB: 1JU4) and is rendered as 


































 Chapter 3 covered the residues that we hypothesize will interact with 
substrate at the putative docking site.  These residues were selected based on 
the crystal structure of cocaine analog RTI co-crystallized with CocE and 
discussed in Chapter 3, as well as from docking poses for cocaine based on MD 
simulations.  These residues include Ala51, Gln55, Leu169, and Ile170. 
The final group of residues contains substrate binding site candidate 
residues that were selected based on models of cocaine-bound CocE and from 
the x-ray crystal structures of the covalent intermediate structure discussed in 
Chapter 4.  More specifically, we selected several residues that we hypothesize 
might be in position to interact with the binding of substrate to enhance its affinity 
or alternatively enhance the release of product benzoic acid.  Residues in this 
group include Phe261, Leu290, Ile307, Leu407, and Phe408.  These mutations are 
presented below.   
Illustrated below is a cartoon of the catalytic triad of a CocE in relation to 
substrate cocaine.  Highlighted are the catalytic residues Asp259, His287 and 
Ser117 representing the acid, base and nucleophile, respectively, that are directly 
involved in the catalysis.  The active site mutations below were designed with this 
classic catalytic triad of an esterase in mind but in the context of the various 
CocE structures now available to our laboratory.   Here, His287 serves as the 
base first involved in first polarizing (ie. accept a proton) the nucleophile (OH of 
Ser117) where it may attack the carbonyl carbon off the benzoyl moiety of cocaine 
and release the negatively charged ecgonine methyl ester.  His287 is then 
deprotonated by ecgonine methyl ester.   This nucleophilic attack results in the 
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first transition state (TS1) and is depicted by acyl intermediate state 1 (AIS1) 
structure described in chapter 4.  Following stabilization of the base (His287) by 
the acid (Asp259) an incoming H2O becomes the second nucleophile following 
deprotonation.  The nucleophilic attack by the OH- on the carbonyl carbon of TS1 
releases yielding a tetrahedral acyl intermediate state (AIS2), a structure closely 
resembling the phenylboronic acid-bound CocE structure (PDB: 1JU3).  Finally, 
the protonated His287 donates its proton to the leaving group, in this case the 
oxyanion of Ser117, and thus the release of benzoic acid. as the leaving group 






Figure 5.3: Catalytic residues involved in hydrolysis of  
(-)cocaine. Illustrated are the residues in the catalytic triad 
involved in the hydrolysis of cocaine by CocE.  
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Substrate binding site residues 
Phe261:  Phe261 is located in the loop region at the beginning of helix E in DOM I 
(Figure 5.4).  The phenyl ring of Phe261 lies 3-3.5 Å away from the phenyl ring of 
benzoic acid (in PDB: 1JU3) and thus a similar distance from the phenyl ring of 
cocaine in our cocaine-bound CocE model.  Phe261, as well as a set of aromatic 
residues including Trp151, Trp166 and Phe408, together form an extensive network 
of van der Waals contacts with the phenyl ring of benzoic acid and presumably 
the substrate cocaine.   
 In order to interrogate the Phe261-phenyl ring interaction, several mutations 
were made to this residue.  Substituting Phe261 with an alanine residue, in an 
attempt to eliminate the van der Waals interaction with the phenyl ring, 
dramatically increased the KM for cocaine at least 320 µM.  We predict that is 
would be an underestimation of the KM since the highest concentration of cocaine 
tested in the assay is 100 µM.  The enzyme does retain some enzymatic activity 
with projected Vmax of 1060 min-1, with the caveat that higher concentrations of 
substrate would be required to yield a better estimation.   
Table 5.1: Kinetic constants of Phe261 mutants 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency 
(µM-1min-1) 
Phe261Ala >200 1100 +/- 600 NC 
Phe261Trp 17 +/- 2.0 2200 +/- 75 132 
Phe261Tyr *ND *ND  
*ND  Not Detectable    
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Mutating Phe261 to Trp produced a mutant that displayed activity with 
similar kinetics to the control CocE used in this assay.  Because tryptophan 
contains an indole ring, it can potentially contribute van der Waals interactions 
with substrate similar to Phe and may be the reason for this mutant’s kinetics.  
Without structural information, again, we are not able to discern how the R-group 
was positioned.  Interestingly, the Phe261Tyr mutant displayed the most dramatic 
change in activity by rendering the enzyme inactive.  The phenyl ring of Phe261 is 
predicted to lie perpendicular to the plane of the phenyl ring of benzoic acid or 
cocaine.  Typically used as a conservative substitution of Tyr, Phe at position 261 
however adds a hydroxyl that in the cocaine model, would protrude into the 
phenyl ring of cocaine and likely inhibit its binding. 
 
Leu290:  Leu290 lies downstream of the active site His287, and is located in the long 
loop region of β8 and β8a strands, similar to Ser288 (Figure 5.5).  We reasoned 
that by increasing the hydrophobic presence of this region that together with 
tryptophan, through minimizing waters found in the active site and to increase the 
Figure 5.4:  CocE residue 261  Panel A contains the native residue F261 in 
magenta.  Mutations to residue 261 include alanine (B), tryptophan (C), and 
tyrosine (D).  The catalytic triad is shown along with the hypothetical position of 
cocaine near active site residues.   
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dielectric constant in the active site.  This in turn should increase the acidity of 
Asp259, and help proton transfer and the overall chemistry of the hydrolysis 
reaction.   
 
Table 5.2: Kinetic constants of Leu290Trp mutant. 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency 
(µM-1min-1) 







Figure 5.5: The location of Leu290 with respect to the catalytic 
triad and substrate cocaine.  The left panel shows the endogenous 
leucine residue at position 290.  The tryptophan mutation is shown in 
the right panel in the orientation that causes the least amount of clash 
with other active site residues.   
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As depicted in table 5.2 substituting the large aromatic Trp side group at 
Leu290 appeared to subtly improve the Km of CocE for cocaine, but an 
accompanying decrease in the maximal velocity compared to WT-CocE.  One 
possible explanation for this result is that this residue sits in close proximity to the 
backbone of Gln55 and Ser56 and thus may help to stabilize the loop-A1 helix-loop 
of DOM1 which forms the solvent facing region of the active site cleft.  Our 
rationale for this mutation was originally to improve the velocity through 
increasing the dielectric constant around His287.  Our results suggest that the 
opposite effect may have resulted whereby we may have inadvertently altered 
access of His287 to a catalytic H2O.  Alternatively, the larger aromatic ring may 
have enhanced van der Waals contacts with the phenyl ring of cocaine, leading 
to in decrease in the KM.  This unfortunately accompanies a decrease in product 
(benzoic acid) release, and hence a decrease in the velocity.   
 
Leu407 and Phe408:  Leu407 and Phe408 both are in a loop region that connects the 
Figure 5.6: The location of Leu407 relative to cocaine   Panel A shows the position 
of native residue leucine at position 407.  Mutations to this residue are shown in the 
next three panels:  alanine (B), phenylalanine (C), and valine (D).   















A	   B	   C	   D	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β1 and β2 strands in DOM3 (Figures 5.6 and 5.7).  Analysis of the CocE models 
bound to cocaine, the transition state intermediates or the product benzoic acid, 
suggest that Leu407 and Phe408 both interact with the benzoyl ring of cocaine  
(PDB: 1JU3, 1JU4 and our acyl intermediate structure ).  This loop inserts 
between DOM1 and DOM3 in CocE but also participates in the CocE’s 
quaternary structure lying at the dimer interface to help form the hydrophobic 
cleft of the active site.  
 
Leu407: The side chain of Leu407 is lies approximately 4Å away from the 
benzoyl ring of cocaine.  Since leucine is one of the smallest of the hydrophobic 
residues, we sought to interrogate both decreasing and increasing the 
hydrophobic potentials at this position.  Surprisingly, the Leu407Ala mutant 
exhibited an improved affinity for cocaine (lower KM~5.7 µM) but, as seen with 
other mutants with an improved KM, there was an accompanying decrease in the 
velocity to approximately half the rate of WT-CocE.  The improvement in KM 
yields appears to outweigh the decrease in Vmax and yields an overall catalytic 
efficiency that is the calculated so far.  Similar results are observed with the 
Leu407Val mutant an improved KM for cocaine accompanies loss in the maximal 
velocity (Vmax ~500 min-1).   
Table 5.3: Kinetic constants of Leu407 mutants. 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency 
(µM-1•min-1) 
Leu407Ala 5.7 +/- 2.0 1100 +/- 40 185 
Leu407Phe >200 2300 +/- 110 NC 
Leu407Val 8.2 +/- 5.3 500 +/- 125 61 
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In contrast, increasing the overall size and hydrophobicity of residue 407 
with a phenylalanine substitution leads to an enzyme with a dramatically higher 
KM (>200 phenylalanine residue yields an enzyme with the poorest activity of the 
three mutations interrogated).  Though the maximum velocity is projected to 
remain within the range of the standard CocE kinetics (~2500 min-1), this is a 
projected value due to the KM (>200 µM) falling outside of the range measurable 
by this assay.  
A possible rational for the behavior of these substitutions at Leu407 may 
involve substrate binding and chemistry.  The proximity of Leu407 to His287 may 
suggest that some substitutions may perturb the position of this very important 
catalytic residue.  Similar to the argument made for the putative mechanistic 
influence of Ser288Thr mutant His287 suggests that Ala and Val side chains may to 
too small and not capable of nudging His287 toward Asp259, part of the catalytic 
triad.  In this manner the velocity and not the KM would be deleteriously affected.  
In contrast, a phenylalanine side chain may simply be too large and potentially lie 
too close to the benzoyl moiety and potentially could impair substrate binding, 
consistent with its deleterious effect on the KM for cocaine.   
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 Another possible explanation for the lower velocity may related to the 
proximity of Leu407 to His287.  As we have now observed His287 undergoes 
considerable movement during catalysis and is located within only 3.5Å of from 
the Leu407 side chain.  Such close proximity may allow L407, perhaps through van 
der Waals interactions, influence this movement and therefore catalysis.  
Removing the interaction through shortening the alkyl chain with an alanine and 
valine substitution could influence the capacity of His287 to serve as a general 
base. 
 
Phe408: Phe408, like Leu407 lies close to both the benzoyl moiety of substrate 
cocaine but also within van der Waals contact of His287(See Figure 5.8). 
Mutations designed to enhance the binding of substrate may also therefore 
interfere with catalysis.  In the case of Phe408Tyr the potential of tyrosine to π-
stack on either His287 (depending on the charge state) and/or the phenyl ring of 
the substrate, the latter would decrease Vmax and the former increase interaction 







Figure 5.7:  Interaction of Leu407 and His287.  A) the CH3 group of Leu407 lies 
within van der Waals distance (3.5Å) away from His287 and influence its 












Summary of single point mutations: 
Single point mutagenesis of the key residues in the active site have 
identified extremely interesting candidates that display enhance kinetic 
constants.  An interesting correlation can be drawn with the mutants that display 
enhanced affinity for substrate, as indicated by the lower KM.  Mutants that 
display lower KM value (higher affinity for substrate) also appear to have lower 
maximal velocities.  A plausible explanation for this dichotomy may be related to 
the fact that improving the overall affinity for the benzoyl moiety of cocaine may 
also improve the affinity for the product benzoic acid.  Since benzoic acid 
Table 5.4:  Kinetics of CocE mutants - Phe408Ala and Phe408Tyr 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency 
(µM-1•min-1) 
F408A 13 +/- 3.3 770 +/- 60 60 
F408Y 23 +/- 4 850 +/- 50 37 
Figure 5.8:  Position of Phe408 mutants with respect to His287 and the 
benzoyl moiety of cocaine  Panel A shows the position of phenylalanine at 
position 408.  Mutations to alanine and tyrosine are shown in the middle and 
right panels, respectively.   
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appears to be the rate limiting step in the hydrolysis of cocaine, slowing the 
benzoic off-rate and hence product release will result in a decrease in the kcat, or 
the velocity of the enzyme for substrate cocaine.  Thus, mutants containing either 
Leu290Trp, Leu407Ala, Leu407V or Phe408Ala all displayed lower KM values but 
lower accompanying maximal velocities, and unfortunately all with lower catalytic 
efficiency.   
A single point mutation the targeted catalysis directly and displayed 
dramatic improvements in the maximal velocity was Ser288Thr.  We hypothesize 
that replacing the serine with the bulkier threonine would stabilize the catalytic 
His287 in a position that could interact more efficiently with the catalytic partner 
Asp259.  A better His-Asp interaction may allow the histidine residue to serve as a 
better general base and proton donor.  This mutant enzyme exhibited the highest 
Vmax and catalytic efficiency observed from a single point mutation to date, 
despite displaying a higher KM than WT-CocE.   
A single point mutation described in Chapter 3, Ser51Glu, originally 
designed to validate whether the RTI-150-bound CocE structure represents 
potential docking site for cocaine, also displayed a significantly lower KM, with a 
moderately low Vmax.  In this model the acidic side chain of the glutamate residue 
interacts with the bridging nitrogen on the tropane ring of cocaine not in the 
active site but in the putative cocaine docking site.  This mutation, as opposed to 
the KM mutants described above, should not alter benzoic acid release (~11Å 
away) and thus exhibit better for cocaine hydrolysis. A mutation at neighboring 
position 55 (Gln55Glu) displayed similar behavior on both KM and Vmax.  By 
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plotting the KM versus the Vmax of the single point mutants analyzed in this study, 
compared to CCRQ and CCKQ reveals an interesting distribution.  With the 
exception of Ala51Glu and Gln55Glu most mutants fell along a linear correlation 








Analysis of CocE combination mutants:   
Figure 5.9: Relationship between the KM and Vmax of the single point 
active site mutants. Mutants that displayed KM values below 200 µM were 
included were compared to CCRQ and CCKQ.  Highlighted in red (Ala51Glu, 
Gln55Glu and Ser288Thr) are the single point mutants that appeared to deviate.  


























We next determined whether combining a mutant that displays a lower KM 
for cocaine with a mutant that displays higher maximal velocities, to form high 
activity hybrid enzymes.  The one mutation showing a higher velocity in this study 
was Ser288Thr (Vmax = 4770 min-1).  Three mutants had improved KM, namely:  
Ala51Glu (KM = 5.5 µM); Gln55Glu (KM = 4.1 µM); and Leu407Ala (KM = 5.7 µM).  
We hypothesize that combining each of these three mutations with Ser288Thr, we 
would create a mutant form of CocE that would offer an improved KM with a 
higher velocity – an enzyme with a superior overall catalytic efficiency.   
 
 Gln55Glu /Ser288Thr: As depicted in Table 5.5, taking advantage of the superior 
KM properties offered by the Gln55Glu mutant and the high velocity of the 
Ser288Thr mutant produced a mutant with intermediate properties that resembled 
the Ser288Thr mutant alone, with a slightly lower Vmax.  It is likely that the 
compromised catalytic activity of the Gln55Glu mutant was incorporated into the 
Ser288Thr without translating the lower KM.  Analysis of the crystal structures of 
the CocE models does not reveal an obvious structural rationale for the lower 
affinity for cocaine offered by this double mutant. 
 
 
Table 5.5: Catalytic constants for KM (Gln55Glu) and Vmax (Ser288Thr) double mutants of 
CocE 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency 
(µM-1•min-1) 
Gln55Glu, Ser288Thr 29.0 +/- 2.1 3400 +/- 100 119 
Gln55Glu 4.1 +/- 0.7 750 +/-30 184 
Ser288Thr 31 +/- 9.0 4800 +/- 50 154 
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Ser288Thr, Leu407Ala:    By combining the KM mutant Leu407Ala with the Vmax 
mutant Ser288Thr another enzyme with an intermediate activity was generated. 
As illustrated in Table 5.6 the Ser288Thr/Leu407Ala double mutant displayed 
activity closely resemble the single Leu407 mutant, with slightly higher KM and 
Vmax kinetic constants for cocaine hydrolysis.  In this case the high Vmax 
properties of the Ser288Thr could not translate into the Leu407 background but did 
retain the low KM (~10 µM).  One possible explanation for this failure may be 
related to the influence of both substitutions on the position of His287.  The 
advantages gained with the Ser288Thr mutation on directing His287 toward Asp259 
may be counteracted by removing the His287-Leu407 interaction and through 





Ala51Glu/Ser288Thr:  As part of the model validation for the RTI-150 structure 
described in Chapter 4 we identified Ala51Glu as a low KM mutant that displayed 
reasonable, but diminished maximal activity (Table 5.7).  This mutant, Ala51Glu, 
displayed the one of the lowest KM value observed in our mutagenesis studies  
Table 5.6: Catalytic constants for KM (Leu407Ala) and Vmax (Ser288Thr) double 
mutants of CocE 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency  
(µM-1•min-1) 
Ser288Thr, Leu407Ala 10 +/- 2.3 1200 +/- 79 120 
Ser288Thr 31 +/- 9.0 4800 +/- 50 154 
Leu407Ala 5.7 +/- 2.0 1100 +/- 40 185 
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 (~5.5 mM).  Combined with the Vmax mutant, Ser288Thr, the double mutant 
displayed an unprecedented maximal velocity of approximately 12,000 min-1.  As 
observed in the previously described double mutants we unfortunately did not 
observe a cooperative enhancement between the two mutants in the KM.  No 




Ala51Glu/Ser288Thr in the CCRQ and CCKQ backgrounds:  Since the 
Ala51Glu/Ser288Thr double mutation exhibited the best overall improvement in 
kinetics compared to other mutants tested, this combination of mutants was 
examined in our best thermostable CocE mutant backgrounds – CCRQ and 
CCKQ.    
By combining the Ala51Glu/Ser288Thr double mutant into either CCRQ or 
CCKQ backgrounds, we generated our most active mutant to date.  The CCRQ 
background did not produce a better mutant than in CC background alone.  The 
KM’s of both thermostable backgrounds worsened, but the improvement in Vmax 
shows that the combination of mutants can produce a superior enzyme with the 
best catalytic efficiency.  
Table 5.7: Catalytic constants for Km (Ala51Glu) and Vmax (Ser288Thr) double 
mutants of CocE 
Mutant KM (µM) Vmax (min-1) 
Catalytic Efficiency  
(µM-1•min-1) 
Ala51Glu, Ser288Thr 70 +/- 9.7 11900 +/- 80 167 
Ser288Thr 31 +/- 9.0 4800 +/- 50 154 
Ala51Glu 5.5 +/- 0.8 920 +/- 40 167 
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Table 5.8: Catalytic constants for Ala51Glu/Ser288Thr in the CCRQ and CCKQ 
background 




CCRQ 26 +/- 2.0 2500 +/- 240 96 
CCKQ 55 +/- 10 6900 +/- 60 126 
Ala51Glu/Ser288Thr:CCRQ 72 +/- 10 11000 +/- 100 151 






By mutating individual residues on CocE we were able to generate several 
mutants although most with better Michaelis constants KM and Vmax.  Single point 
analysis revealed three mutants, Ala51Glu, Gln55Glu, and Leu407Ala that 
displayed improved KM values and only one mutant, Ser288Thr that displayed 
significantly higher maximal velocity, Vmax.  In combining these single mutants 
into double mutants, we found one combination with the best Vmax to date 
(Ala51Glu, Ser288Thr).  Finally, through inserting this combination into the most 
active and thermostable mutant background (CCKQ), we generated the most 
efficient enzyme yet developed by this laboratory.  Several potential explanations 
for why these changes can be drawn from structural analysis of the new 
mutations.  At the same time, we saw a definite pattern emerge in the single 
mutations that held true in the combination mutations, which follow the pattern of 
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a structural-function trade off [11-13].  Each mutant that had an improved KM or 
Vmax also showed a decrease in the other kinetic parameter.  Fortunately, we 
were able to combine mutants to generate an improved Vmax that with a 
proportionally lower penalty on KM (Ala51Glu/Ser288Thr:CCKQ).  The KM for 
cocaine of Ala51Glu/Ser288Thr:CCKQ is higher than for CCKQ (KM~50 µM) and 
more so than WT-CocE (KM~25 µM) however the gain in velocity outweighs the 
loss.   
To begin analyzing the results from this study, we should first consider the 
cocaine itself.  The cocaine molecule has several structural elements that could 
potentially interact with CocE residues or the peptide backbone.  The tropane 
ring of cocaine consists of a carbon ring containing a single nitrogen atom.  The 
cyclical structure of tropane allows for hydrophobic interactions and the nitrogen 
atom can form hydrogen bonds with residues nearby.  The carbonyl oxygens 
coming off of the two ester bonds can be hydrogen bond acceptors.  The 
benzene ring, opposite the tropane ring, can have hydrophobic interactions, π-π 
stacking, and cation- π interactions.  Lastly, the methyl groups attached to the 
nitrogen atom and the ester bond, not forming the benzoic acid, can have 
hydrophobic interactions.  Overall, we took advantage of the multiple 
hydrophobic interactions by increasing (Leu290Trp) or decreasing (Leu407Ala) the 
size of the residue on CocE to interact with cocaine.  We intended to increase the 
hydrophobic interaction in order to increase binding of substrate, and conversely, 
we wanted to decrease this interaction in order to facilitate product release.  
Unfortunately, most of the mutants that displayed a decrease in the KM, 
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presumably through increasing substrate affinity, but a decrease in the Vmax, 
presumably through increasing the affinity for the product and hence slowing 
product release even more.   This is likely the reason that in two mutations, 
Ala51Glu and Gln55Glu, we could take advantage of the interaction between the 
acidic glutamate residue and the nitrogen bridge on the tropane ring to increase 
the binding of substrate and improve KM.   Here we did not encounter large 
penalties on the enzyme velocity, since we were not altering the interaction and 
thus affinity for the product nor its release, or at least not the rate-limiting product, 
benzoic acid. 
 Looking at the results from the perspective of the enzyme, we proceeded 
to explore residues in two distinct regions of CocE:  in the active site, based on 
the positioning of the active site triad and the initial structural study; and in the 
putative binding/desolvation site, due to our interpretation of previous structural 
studies described in Chapter 3 of this thesis coupled with the MD simulation 
performed in Huang et al (2014)[7, 14]. 
 Our results from mutagenesis studies support that a structural-function 
trade off that has been found in engineering other proteins [13].  Several 
mutations displayed increased affinity for substrate but expressed a decrease in 
the maximal velocity, possibly due, as mentioned previously, to the enhanced 
affinity for product, benzoic acid.  
Although not fully optimized the combination of Ala51Glu/Ser288Thr-CCKQ 
expressed an enzyme that may, however, already be useful for treatment in 
cocaine addiction and toxicity.  The Km, albeit relatively high, is within 
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reasonable levels found in cocaine addicts and in over-dosing individuals, where 
cocaine plasma concentrations reach 25-50 mM and 50-150 µM, respectively [3, 
4, 15].  We look forward to testing the effect of this combined mutant in animal 
studies to test its capacity to modify self-administration models of cocaine abuse 
as well as cocaine-induced lethality in rodents.  We also look forward to 
analyzing the crystal structure of this mutant to both validate the proposed model 
for the catalytic efficiency enhancement and also utilize the structure to further 
enhance its catalytic properties.    
 
  
Figure 5. 10:  Michaelis-Menton plot of all single mutants covered 
in Chapter 5  Kinetics of all mutants with potential to interact with 
substrate are plotted and values for Vmax and KM are shown in the 
table below.       
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Figure 5.11:  CocE double mutants for increased enzyme efficiency.    
Single mutations A51E, Q55E, or L407A were combined with S288T in 
order to generate a CocE mutation with better overall enzyme efficiency.  
Michaelis-Menton plot is shown for each mutant compared to RQ-CocE 
control.  Kinetic parameters for each mutant are shown below.   
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Conclusions and Future Directions 
 In just under two decades, cocaine esterase went from a little known 
enzyme dwelling in the Rhodococcus MB1 bacteria growing in the soil near the 
roots of the Erythrozylum coca plant to a valid candidate for treating cocaine 
toxicity and addiction in humans.  For over ten years of that journey, we have 
been engineering cocaine esterase into a future therapeutic.  Our earliest efforts 
to engineer this protein included increasing the thermostability profile of the 
enzyme, elucidating the metabolic profile of the enzyme, and its breakdown in 
circulation[1-4] (reviewed in [5]).  During these studies, two different aspects of 
the enzyme became clear and needed to be addressed:  1) the short in vivo half-
life of CocE; and, 2) increasing the overall efficiency of CocE.  The research 
contained in Chapters 2 - 5 of this thesis addressed these issues.   
The major findings of the studies in the previous three chapters can be 
summarized as follows: 
-­‐ PEGylation of CocE occurs at a single cysteine residue (C551), and 
attachment of one or two additional PEG molecules per monomer will 
generate 24 hr further protection (>72 hr in total).   
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-­‐ Cocaine may temporarily bind to CocE at a site outside of the catalytic 
triad in a putative docking site prior to moving into the active site for 
hydrolysis 
-­‐  CocE mutant CCKQ-Ala51Glu:Ser288Thr produced the best catalytic 
efficiency of any enzyme from our lab to date.   
Combining these results to generate a PEG-CCKQ-Ala51Glu:Ser288Thr-CocE 
protein may provide the best candidate for treating cocaine addiction to date.   
 Though this CocE mutant offers the most desirable kinetics for breaking 
down cocaine in situ, two immediate issues need resolving.  These issues are:  
1) The ability of CocE to recondition away from cocaine seeking; and, 2) CocE’s 
ability to metabolize cocaine for longer than 3-4 days.  
 
One of the most common questions/critiques to this work is that all of our 
in vivo assays demonstrate protection against cocaine toxicity; however, we are 
attempting to produce a protein-based therapeutic to treat cocaine addiction.  
The previous research to support CocE as a tool to provide the reconditioning 
against cocaine seeking behavior has not been discussed in this thesis so far, 
but needs addressing.  The study covered in Collins et al demonstrates the ability 
of RQ:CocE to alter the cocaine seeking behavior of rats that have been 
conditioned to seek cocaine[6].  By dosing rats with RQ:CocE, their cocaine 
craving decreases demonstrated their response to cocaine injection dropping to 
the same level as saline injection. (Figure 6.1)  As the data shows, at higher 
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concentrations of cocaine, the reconditioning away from cocaine seeking 
behavior provided by CocE begins to wane.   
 We hypothesize that having a more efficient enzyme, especially if we are 
able to improve the KM value of our best mutant, Ala51Glu:Ser288Thr-CCKQ, then 
we will provide the best candidate for treating cocaine addiction.  To that end, we 
feel that additional mutations on top of our current, optimized version could hold 
the key to unlocking an even more efficient enzyme and potential therapeutic.  
The discussion of each mutation provided a rational for the biochemistry that 
resulted from the mutations.  By expanding the number of mutations at each 
position, we could further expand on this explanation and develop a more 
Figure 6.1:  CocE can recondition rats away from cocaine seeking 
behavior.  Rats, conditioned to self-administer cocaine, were 
pretreated with either saline or CocE [WT or RQ (DM)].  During an hour 
observation period, rats treated with RQ CoE sought cocaine at the 
same level as those responding to saline.   
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complete model of CocE than what we currently have, in terms of catalytic 
efficiency and stability.   
 
Though we have achieved a level of success in extending the in vivo 
activity of CocE using PEGylation, we hypothesize that extending limit could be 
achieved through coupling PEG:CocE with another method of formulation that we 
have tried previously.   
One of the early attempts to extend the in vivo activity of CocE involved 
encapsulating PEG:CocE into the biodegradable polymer, PLGA, poly(lactic-co-
glycolic acid).  PLGA encapsulation has been used as a method to provide 
sustained release of therapeutic molecules[7, 8].  Briefly, a small molecule or 
protein is trapped within a millicylinder or nanoparticle of PLGA.  Once the 
nanoparticle is inserted into the skin of an animal, the PLGA polymers begin to 
degrade and the target drug is released into the circulation of the animal.  
Release from PLGA millicylinder can proceed for up to 45 days [9].   
In a collaborative effort with Steven Schwendeman (University of 
Michigan), we attempted to encapsulate PEG-CCKQ CocE in PLGA 
nanoparticles.  Our efforts to obtain a nanoparticle of PEG:CocE were marginally 
successful.  During the majority of the encapsulation experiments, the protein 
aggregated during encapsulation; however, on our last effort, we were able to 
recover soluble protein from a nanoparticle.(Figure 6.2A and B)   
Unfortunately, we were unable to detect any activity in this protein. (Figure 
6.2C)  Though we were not able to generate any useable material, we were 
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encouraged by the success of the collaborating group’s ability to deliver other 
therapeutic proteins[10].  If we are able to build on this preliminary result, we 
could potentially extend the protective effect of CocE from several days to 
several weeks.   
 If we are able to deliver the most effective enzyme for hydrolyzing cocaine 
for over a month to an addict, we believe that this therapeutic will indeed be a 
strong competitor to address the unmet need of an FDA approved therapeutic to 







Figure 6.2  PLGA encapsulation data with CCKQ-CocE. A) Quantification of CocE that 
aggregated during PLGA encapsulation.  Acetone RT = acetone at room temperature, 
acetone 37 = acetone warmed to 37°C prior to mixing with PLGA and protein mixture.  B)  
SDS-PAGE of samples from PLGA released protein during time course.  Left lanes show 
soluble material released, and right lanes contain aggregated material. C) CocE activity assay 
performed with soluble material released from PLGA millicylinder. Only PEG-CCKQ and 
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In summary, we feel that we have made great progress toward developing 
a treatment for the cocaine addiction and intoxication.  We have used a structure-
based approach to understand the catalytic mechanism of cocaine esterase.  
With these models in hand we have used the structure to designed, engineered 
and tested mutant forms of cocaine esterase with superior catalytic properties 
and stability. We will continue to take this structure-based approach to optimize 
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